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Medication complexity and nonadherence are significant risk factors for avoidable 
hospitalizations and health care spending for older adults in the United States. However, 
limited empirical research has investigated pharmacist-run telephonic medication 
management programs as a potential solution to the problem of reducing medication 
complexity while improving medication adherence.  This quantitative study employed the 
behavioral change model to analyze archival data from a sample of 1,148 participants, 
examining the relationship of a pharmacist-run telephonic consulting program on 
medication adherence and medication complexity for one pharmacy benefit management 
firm’s Medicare Part D recipients.  The primary research questions investigated the 
relationship of medication therapy management programs to medication adherence and 
complexity.  Data were assessed using correlation and regression analysis to determine 
the association between receiving pharmacist counseling, medication adherence, and 
medication complexity, and to assess the strength of any relationships identified.  No 
linear relationship was found between pharmacists’ counseling, medication complexity, 
and medication adherence.  However, the study found a weak correlation between 
medication complexity and comorbidities, and between medication complexity and 
medication adherence.  This study promotes positive social change by identifying 
information that can be used to reduce pharmaceutical industry liability by improving 
proper management of medications, by reducing the burden of comorbidities related to 
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Chapter 1: Introduction to the Study 
Managing chronic diseases is often challenging for older adults who are aged 65 
years and older.  Multiple comorbidities, numerous medications, multiple health care 
providers, and other factors contribute to medication nonadherence and self-management 
issues for all individuals, but they have an additional impact on older adults 
(MacLaughlin et al., 2005; NEHI, 2009; Smith, Catellier, Conlisk, & Upchurch, 2006).  
Medication nonadherence is responsible for $100 billion in avoidable hospitalizations and 
$290 billion per year in avoidable health care spending in the United States (NEHI, 2009; 
Osterberg & Blaschke, 2005).  Managing a chronic disease such as Type 2 Diabetes 
Mellitus (T2DM) in older adults is especially challenging because of the complex 
medication regimens and the existance of comorbitities (ADA, 2013).  For T2DM 
patients, reaching their clinical outcomes and goals is key to effective disease 
management (ADA, 2013).  This study investigated methods to improve medication 
adherence for older adults with T2DM.   
This study examined a U.S. pharmacy benefit management (PBM) company’s 
medication therapy management (MTM) system and its impact on medication adherance. 
In this system, pharmacists use telephone consulting in order to decrease medication 
complexity and nonadherence to prescribed medications.  While these management 
practices are designed to benefit the individual patient, this strategy has the potential to 
create positive, systemic changes for society.  Increasing the proper management of 
medications will positively impact the pharmaceutical industry by reducing liability, 




management of chronic disease, and streamline health services to imrpove their outcome 
(Lawrence, Qu, & Briskin, 2012; NEHI, 2009; Viswanathan et al., 2012). 
Chapter 1 introduces the study topic and provides background information on 
T2DM, medication nonadherence, PBM companies, and MTM pharmacist counseling 
program.  After presenting the problem statement, purpose and research questions, I will 
briefly summarize stages of change theory and how this theory applies to medication 
nonadherence.  The chapter continues with the nature of the study, definitions, and a 
discussion of the study’s assumptions, limitations, scope, and delimitations.  The chapter 
concludes with a discussion of the study’s significance and a chapter summary.  
Background 
Self-management of T2DM in older adults is challenging because of complex 
medication regimens and the coexistance of comorbidities such as hypertension and 
hyperlipidemia (ADA, 2013; Inzucchi et al., 2012).  Successful management of treatment 
depends not only on achieving proper glycemic control but on achieving treatment 
balance between comobidities and quality of life (Pratley & Gilbert, 2012).  The 
prevalence of T2DM increases with increased life expectancy for older adults (Inzucchi 
et al., 2012; Pratley & Gilbert, 2012).  The Centers for Disease Control and Prevention 
(CDC) estimated that in 2010, 390,000 older adults in the United States were newly 
diagnosed with T2DM (CDC, 2011). Despite the high consumption of prescription 
medications by older adults, it is not age itself but the age-related comorbidities that have 
a high risk of polypharmacy (multiple medication use). Polypharmacy correlates with 




and mortality (Budnitz, Lovegrove, Shehab, & Richards, 2011; Mansur, Weiss, & 
Beloosesky, 2012).  For older adults with T2DM, diabetes treatment is often intensive 
and complex, creating challenges with medication adherence. 
Pharmacy Benefit Management Companies 
Pharmacy benefit management companies are specialized firms that manage the 
prescription drug programs for most health plans (Lawrence et al., 2012).  These 
companies provide cost-effective drug-related administrative services and improving 
medication adherence, resulting in positive patient outcomes.  Pharmacy benefit 
management companies promote medication adherence and improve health outcomes by 
employing disease management (DM) programs that primarily focus on chronic 
conditions such as diabetes, hypertension, arthritis, hyperlipidemia, and heart failure.  In 
PBMs, pharmacists may be at the leading edge for DM programs (Lawrence et al., 2012);  
these pharmacists attempt to work proactively to educate patients on chronic conditions 
and monitor programs designed to increase medication adherence. 
Medication Complexity 
There is a limited body of literature on PBMs’ use of MRCI scores on medication 
nonadherence.  Medication variables such as the number of medications, dosing 
frequency, instructions, and prescribed dosage forms can all negatively affect adherence 
(George, Phun, Bailey, Kong, & Stewart, 2004).  These are measured in part by the 
Medication Regimen Complexity Index (MRCI), which provides a numeric value that 
reflects medication variables (formulation, dosing frequency, and special instructions) 




over-the-counter herbals or supplements; George et al., 2004).  A review of the extant 
research, detailed more thoroughly in Chapter 2, suggested that certain chronic disease 
medication regimens are more complex than others are.  In addition, medication 
complexity has been positively correlated with medication nonadherence (Choudhry et 
al., 2011; Libbey et al., 2013; Moore, Shartle, Faudskar, Matlin, & Brennan, 2013; 
Pollack et al., 2010).   
Medication Adherence 
Medication adherence is a complex behavior that depends on self-efficacy to 
perform the behavior, confidence in one’s medical providers, and a belief that the 
medication treatment will work (DiMatteo, Haskard, & Williams, 2007).  Medication 
misuse and nonadherence result in the deterioration of a patient’s chronic condition and 
increased hospitalizations and medical costs (Ho et al., 2006; Hughes, 2004; Mahoney, 
Ansell, Fleming, & Butterworth, 2008). Interventions that include simplyfing drug 
regimens, increasing patient education, and pharmaceutical counseling increases 
medication adherence (Rodriguez de Bittner & Zaghab, 2011; Viswanathan, 2012). 
Increasing medication adherence is complex, and may require more than one solution to 
be successful. 
At the time of this study, pharmacy benefit management companies in the United 
States used two methods to measure medication adherence using pharmacy claims data: 
medication possession ratio (MPR) and proportion of days covered (PDC).  Both MPR 
and PDC allow PBM pharmacists to monitor a patient’s adherence and to intervene when 




I used MCRI scores to help identify medication complexity and MPR ratios to measure 
adherence in a cohort of patients receiving medications in the treatment of T2DM.  
Medication Therapy Management Programs 
The Medicare Prescription Drug, Improvement and Modernization Act of 2003 
(MMA 2003) was a U.S. Congressional health care reform bill that focused on preventive 
medicine for chronic diseases to develop a mechanism to improve the quality of 
medication management (Neuman & Cubanski, 2009).  The centerpiece of this reform 
bill offered Medicare beneficiaries outpatient prescription drug benefits (Meyer & 
Cantwell, 2004; 108th Congress, 2003).  To ensure drug safety and appropriateness for 
the targeted beneficiaries, MMA 2003 required that all Medicare plan sponsors establish 
and implement a medication therapy management (MTM) program. 
Medication therapy management is a part of the family of DM programs and is a 
distinct set of services designed to optimize therapeutic outcomes for the Medicare Part D 
recipients (Schommer, Doucette, Johnson, & Planas, 2012). MTM programs are distinct 
from other DM programs because of they incorporate analysis of a patient’s total 
medication experience, not just the single chronic condition (Pellegrino, Martin, Tilton, 
& Touchette, 2009). While many MTM programs deliver through face-to-face 
consultations, several studies have shown that this delivery system is not always optimal 
for the patient and the community pharmacist (Dolor, Masica, Touchette, Smith, & 
Schumock, 2012; Schommer et al., 2012).  Feifer, Greenberg, Rosenberg-Brandl, and 
Franzblau-Isaac (2010) found that some patients are not always satisfied with 




telephone consultations have been proposed as a viable alternative to deal with this 
dissatisfaction (Moczygemba et al., 2008; Ward & Xu, 2011; Wu et al., 2006).   
Pharmacy benefit management companies are well-equipped to offer full clinical 
pharmacist services, including MTM programs via telephone, to all Medicare health 
maintenance organizations and other private insurance companies (plan sponsors) that 
provide Medicare covered benefits (Neuman & Cubanski, 2009). The availability of 
complete patient medication profiles via electronic data claims enables PBM MTM 
pharmacists to remotely identify individuals who have the propensity to be medication 
nonadherent.  Telephone MTM services are an option to deliver patient-specific care for 
health care plans offering MTM services to Medicare recipients. Pharmacists’ direct 
patient care interventions have been shown to improve health care outcomes (Rodriguez 
de Bittner & Zaghab, 2011; Schnipper et al., 2006; Moczygemba, Barner, Gabrillo, & 
Godley, 2008).  However, this study’s review of the literature indicated a gap in the 
research investigating PBM MTM pharmacist counseling on medication complexity and 
improved adherence.  
Problem Statement 
As the U.S. population ages, more people are being diagnosed with Type 2 
Diabetes Mellitus (ADA, 2013). T2DM is a complex and lifelong chronic disease that 
requires multiple medications, effective self-management, and medication adherence to 
achieve therapeutic success (ADA, 2013).  Many older adults with T2DM have existing 
comorbidities such as hypertension, hyperlipidemia, and coronary heart disease, which 




patients with T2DM who are medication nonadherent are at greater risk for 
hospitalizations, emergency department visits, and all-cause mortality (Ho et al., 2006; 
Lau & Nau, 2004; Yang et al., 2009). Complex medication regimens also have 
documented negative effects on medication adherence and therepeutic outcomes 
(Choudhry et al., 2011; Libby et al., 2013; Pollack, Chastek, Williams, & Moran, 2010).  
Medication complexity and nonadherence have the propensity to undermine effective 
treatments in complex chronic diseases such as T2DM. 
There is a gap in the literature on the effectiveness of PBM telephonic systems 
that pharmacists use to engage patients; however, several previous studies suggest that 
this is an important area for research.  Several studies have suggested that lack of patient 
engagement in their health care is affected by embarrassment, inadequate reading 
comprehension, and poor communications skills, posing a challenge to dispensing 
pharmacists at the store level (Kirsh, Jungeblut, Jenkins, & Kolstad, 2003; von Wagner, 
Steptoe, Wolf, & Wardle, 2009).  Inadequate patient engagement has been correlated 
with a decrease in self-management, affecting decisions in self-care (Mosen et al., 2007).  
Counseling older adult patients in an environment without barriers can increase patient 
engagement and medication adherence (Schnipper, et al., 2006; Tkacz, Metzger, & 
Pruchnicki, 2008).  Other researchers have evaluated hospital-based pharmacists using 
telephone calls for consultation and was deemed successful as a communication medium 
for increasing patient involvement with their treatment (DeWalt et al., 2006; Nazareth et 




Medication therapy management programs in the United States are designed to be 
distinct from medication-dispensing services and other DM programs.  While studies 
have been completed using community pharmacy-based DM programs on patient 
medication adherence (Chawla, 2012; Fox, Ried, Klein, Myers, & Foli, 2009; Planas, 
Crosby, Mitchell, & Farmer, 2009), there has been little research on the impact of MTM 
pharmacists on medication complexity and medication adherence from a PBM system 
using telephonic consulting.  More research is needed to study the impact of MTM 
programs on medication complexity and medication adherence in the older adult 
population. 
Purpose of the Study 
The purpose of this quantitative study was to examine the effects of a pharmacist 
PBM MTM telephonic consulting program on medication adherence and medication 
complexity for a selected PBM’s Medicare Part D recipients.  In this study, I used MRCI 
scores as an indicator for medication complexity, and MPR ratios as an indicator for 
medication adherence.  I specifically examined an MTM telephonic program used by one 
PBM for Medicare patients with T2DM (these indicators are further examined in Chapter 
3).  I sought to analyze whether MTM pharmacist counseling is a means to improving 
medication adherence and compliance in an older adult population.  Increased medication 
adherence and compliance could help stem the high costs of unscheduled hospital and 





Research Questions and Hypothesis 
In this study, I evaluated the association of MTM pharmacist telephonic support 
with medication complexity and nonadherence in a group of T2DM Medicare–D 
beneficiaries enrolled in a specific PBM’s MTM program.  The independent variable was 
the PBM MTM pharmacist-counseling program, and the dependent variables were 
medication complexity (as measured by a decrease in MRCI scores) and medication 
adherence (as measured by an increase in MPR percentages).  This investigation was 
guided by two primary research questions. 
 Research Question 1: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in 
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores 
after controlling for age, gender, and comorbidities? 
H01: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in 
MRCI scores after controlling for age, gender, and comorbidities.  
HA1: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after 
controlling for age, gender, and comorbidities. 
Research Question 2: Is there an association between medication therapy 




beneficiaries having T2DM as measured by a change in MPR percentages after 
controlling for MRCI scores? 
H02: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in 
MPR percentages after controlling for MRCI scores.  
HA2: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores. 
The Theoretical Framework 
This study used the stages of change (SOC) theory for its theoretical framework. 
SOC is a frequently used theory to explain behavior change (Prochaska & DiClemente, 
1983).  This model describes the stages of readiness, the decisional balances, and self-
efficacy used by individuals in making a behavior change.  Changing behavior such as 
starting a new medication or taking medication on a daily basis for a chronic illness is 
difficult for many individuals.  Pharmacists can assist individuals who may require 
information, education, guidance, or a combination in order to be medication adherent.  
The five stages of SOC theory are instrumental in identifying a patient’s readiness for and 
barriers to change;  SOC has been applied extensively where change in behaviors has 
been warranted (Prochaska, Redding, & Evers, 2008) and to explain medication 




Pharmacists can lessen patient frustration and improve patient success by 
understanding the patient’s stage of change, anticipating barriers to change, and 
identifying patients who have relapsed (Prochaska, 2008).  As pharmacists identify 
patients in the different SOC stages, pharmacists can take specific actions by 
recommending an appropriate intervention aimed at increasing adherence.  For long-term 
behavior change (e.g., chronic medication adherence), potential change strategies are 
individualized and applied at every stage (Prochaska, 2008).  As a patient’s skill and 
confidence, increases in managing medication use, challenges, and health crises decline 
(Hibbard, Mahoney, Stock, & Tusler, 2007).   
Nature of the Study 
In this quantitative study, I analyzed secondary data from a quasi-experimental 
match-control study on older adults who had T2DM and associated comorbidities 
(Moore, Shartle, Faudskar, Matlin & Brennan, 2013).  The original study population 
consisted of older adults (≥ 60 years) from a large employer group, with data collected 
from October 1, 2007 through November 12, 2008.  Through the present study, I sought 
to evaluate the effectiveness of a pharmacist MTM program on medication adherence (as 
measured by a change in MPR) and medication complexity (as measured by change in 
MRCI scores) in one PBM’s employer-based Medicare population.  The archival data 





Health literacy:  “The degree to which individuals have the capacity to obtain, 
process, and understand basic health information and services needed to make 
appropriate health decisions” (IOM, 2004 p. 32). 
Medication adherence:  “The collaborative relationship between the patient (and 
or caregiver) and his or her health care providers, leading to the patient's or caregiver’s 
medication behavior coinciding with medical advice” (MacLaughlin et al., 2005 p. 232). 
Medication complexity:  The number of drugs, dosage frequency, administration 
frequency, and the prescribed dosage forms that make up a patient’s medication regimen 
(George et al., 2004).  
Medication therapy management:  “A distinct service or group of services that 
optimizes therapeutic outcomes for individual patients that is independent of, but can 
occur in conjunction with, the provision of a drug product” (APhA & NACD, 2005 p.3). 
Patient-centered service:  Health care providers who work one-on-one with 
patients to understand their perspectives, needs, and concerns regarding their medications 
(Oliveira, 2012). 
Pharmacy benefit managers (PBM):  “Third-party administrators responsible for 
administrating clinically based services that enable them to manage drug spending for 
their clients by improving price competition and increasing the cost-effectiveness of the 
medications covered under client plans” (PCMA, 2003 p.iii). 
Self-management education programs:  “Patient education in preventive and 




designed to facilitate adoption of health-promoting behaviors” (Warsi, Wang, LaValley, 
Avorn, & Solomon, 2004 p. 1641)  
Targeted population:  “Beneficiaries who have multiple disease states (typically 
chronic conditions), use multiple Part D – covered medications, and are expected to 
research (and exceed) the spending limit for the year” (Siecker, 2010 p.2). 
Assumptions 
Several assumptions informed this study.  I assumed that all the pharmacists used 
the same technique when reviewing the patients’ medication records and lab values and 
assessing any initial primary drug therapy concerns.  Differences in techniques used 
could influence the patient’s decision to opt in to the program.  Another assumption was 
the data entered into the PBM's database were accurate.  An additional assumption was 
that all the individuals took their medications as reflected by the MPR scores from the 
original data.  Finally, I assumed that there was no pattern to any missing information.  
Overt inaccuracies and a pattern of missing data could have biased the study results.  
Scope and Delimitations 
The scope of this study was dictated by the source of the archival data: one 
PBM’s MTM pharmacist telephonic counseling service and related changes in 
medication adherence, complexity, and patient engagement collected from older diabetic 
patients from October 1, 2007 through November 12, 2008.  For this study, the archival 
data from the PBM were delimited to adults 60 years and older who had a diagnosis of 
diabetes, were high-end prescription users, and have documentation in their patient 




of drug therapy contraindicated in the treatment of diabetes.  High-end prescription users 
were identified as participants having 14 or more prescriptions within a 120-day period.  
Exclusionary delimitations were those participants with dual coverage from Medicare and 
Medicaid or without active prescriptions.  This study was delimited to the examination of 
MTM counseling service on medication adherence and medication complexity, and I did 
not consider any association with health care costs, as Moore et al. (2013) covered their 
study.  I measured medication adherence by using MPR ratios, and MRCI scores to 
measure medication complexity.  The results of this study were intended to be 
generalizable to adults 60 years and older with T2DM. 
Limitations 
The most important limitation in this study was the use of archival data from a 
previous study of health care in a large PBM (Moore et al., 2013).  Selection, quality, 
included variables, and the method of data collection were not under my control, and 
validation was not possible.  The data set includes both intervention and control group.  
The control group was formed from patients who declined to participate in the opt-in 
MTM counseling service. Moore et al. (2013) used propensity scoring, matching the 
control to the intervention group on several characteristics: age, gender, baseline days 
supply of medications, baseline plan-paid pharmacy costs, physician visits, inpatient 
visits, outpatient visits, and number of pharmacy derived conditions.  Another limitation 
was that individuals who chose to accept the invitation for the opt-in program might have 
been inherently different in some immeasurable characteristics that could have 




index was added to the data set and was not used by the pharmacists initially in the 
evaluation of patient profiles. 
Significance 
Medication complexity and medication nonadherence have been implicated in 
undermining effective chronic disease management.  This, in turn, leads to poor 
medication management and increases in health service users.  Medication nonadherence 
has been implicated as a major contributor to health care costs in the United States.  Costs 
due to medication nonadherence and the ensuing morbidity and mortality are primarily 
borne by insurers, self-insured employers, and government agencies (Shrank, Porter, Jain, 
& Choudhry, 2009).  Pharmacy benefit management MTM telephonic programs provide 
a unique opportunity to promote health by assisting patients to receive the appropriate 
medication and to adhere to their medication regimens.   
Pollack et al. (2010) demonstrated that as the regimen complexity increases, 
medication adherence decreases, adding to disease burden in patients with T2DM.  
Identifying medication complexity was designed to provide PBM MTM pharmacists a 
more efficient approach to identifying high-risk patients.  As a result, targeted 
interventions could improve adherence and achieve optimum outcomes in diabetes 
management, potentially reducing morbidity and mortality.  Using medication 
complexity as an indicator to identify medication nonadherence may be a useful strategy 
for PBMs to reduce long-term costs and decrease downstream costs to payers.  Pharmacy 




directly as many patients are under, over, or inappropriately prescribed medications for 
chronic conditions, which may lead to nonadherence.  
Summary 
For older adults, barriers such as treatment regimen factors (treatment complexity, 
side effects, and dosing schedule) are more difficult to traverse than other factors such as 
disease factors (symptom prominence and disease response), or environmental factors 
(lack of family and social support), adding to medication nonadherence (Ingersol & 
Cohen, 2008).  Medication nonadherence could contribute to adverse events and reduce 
the patient's self-management of their chronic medical condition.   
Medication therapy management programs, a product of MMA 2003, are 
designed to be distinct from other chronic disease programs and could be delivered face-
to-face or via the telephone.  Pharmacy benefit management companies are in an 
excellent position to delivers MTM programs, as these companies have the tools 
necessary to deliver prescription benefits while controlling prescription drug costs.  
Medication therapy management programs, part of the DM programs, is but one of the 
tools used by PBMs to control medication utilization and decrease health care costs.  
Medication therapy management programs use a comprehensive patient-centered 
approach in order to increase patient education on prescription medications, improve 
treatment regimen factors, increasing medication adherence and reduce adverse events.   
This chapter contained an overview of the research objectives, theories, and detail 
of the specific research questions for this study.  The aim of this study was to evaluate 




engagement in the Medicare Part D beneficiaries.  Descriptions of the nature and purpose 
of the study, study design, scope, limitations, and significance of the study were 






Chapter 2: Literature Review 
Introduction 
The purpose of this study was to assess a specific type of  pharmacy benefits 
management’s (PBM) disease management (DM) program service known as medication 
therapy management (MTM).  The MTM pharmacist counseling program examined in 
this study was part of a PBM telephonic system for providing MTM services to Medicare 
recipients.  Pharmacy benefit management MTM pharmacist counseling is based on 
increasing patient engagement and medication adherence to optimize therapeutic 
outcomes.  The stages of change (SOC) model was used to guide the overall research 
framework. 
This chapter discusses the current literature related MTM programs for older 
adults, and is divided into eight sections.  The first section investigates the stages of 
change model of health behavior change and this theory’s application to MTM programs.  
The second section examines literature pertinent to medication nonadherence.  The third 
section provides the underpinnings of MTM and community pharmacists as related to 
increased patient engagement and medication adherence in targeted Medicare 
beneficiaries.  The fourth section focuses on key elements of treating chronic diseases 
and its relationship to patient self-management and medication nonadherence.  The fifth 
section provides background on PBMs and pharmacists’ responsibilities for the various 
clinical services.  The sixth section briefly examines the health care of older adults and 
provides the foundation of the Medicare Prescription Drug, Improvement, and 




(prescription drug benefit portion of MMA 2003) and the offerings of MTM services to 
older adults.  The eighth section examines MTM’s pertinence to medication adherence.  
MTM use by PBM pharmacists is used to improve medication compliance and adherence 
in older adults.  This service originated from the Medicare Modernization Act of 2003 
and the Medicare Part D prescription drug benefit that began on January 1, 2006.  At the 
time of this study, there was a limited body of peer-reviewed literature directly related to 
MTM delivered by PBM pharmacists using telephonic consulting modes. 
Literature Search Strategy 
The literature search for this study was conducted using several multidisciplinary 
databases available from Walden University.  These databases included Academic Search 
Complete/Premier, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Health & Medical Complete, Medline, ProQuest Central, PubMed, Sage 
Premier, and Science Direct.  The search primarily focused on articles published between 
2004 and 2015; older articles were incorporated when deemed necessary.  The search 
keywords included chronic disease management, health literacy, Medicare Modernization 
Act 2003, medication adherence, medication management, medication regimen 
complexity index, medication therapy management, pharmacist, pharmacy benefit 
management, self-efficacy, and telephone consulting.  Multiple books, book chapters, and 
relevant articles were also consulted with a specific focus on the SOC model.  
Theoretical Framework 
Changing medical behaviors such as starting a new medication or continuing to 




nonadherence is a significant problem in the United States, especially for individuals with 
chronic disorders requiring maintenance medications, such as heart failure, diabetes, and 
HIV infection (ADA, 2013; Pratley & Gilbert, 2012).  The reasons for intentional 
medication nonadherence are numerous (Doggrell, 2010; Lehane & McCarthy, 2006; 
Santhosh & Naveen, 2011).  To improve medication adherence, the causes of 
nonadherence must be understood and addressed using numerous multifactorial strategies 
employed by health care professionals (Brown & Bussell, 2011).  Ultimately, however, 
the degree of adherence depends on a patient’s involvement in their own treatment 
decisions. 
This study is guided by the SOC model, which was originally developed to guide 
research on how to quit smoking (Prochaska & DiClementi, 1983).  The results from that 
research revealed that behavior change is gradual, continuous, and occurred in stages 
(Frankish, Lovato, & Poureslami, 2008; Prochaska & DeClemente, 1983).  SOC theory 
was used by researchers in public health, health promotion, and addiction studies because 
the theory incorporated various processes and principles of change from leading 
psychotherapy theory (Ficke & Farris, 2005; Prochaska, Redding, & Evers, 2008).  When 
applying SOC theory, a matched strategy to help the individual successfully use a new 
behavior is identified according to their state of readiness. 
The core constructs of SOC are precontemplation, contemplation, preparation, 
action, maintenance, and termination (Prochaska, 2008).  The theory’s central premise is 
that individuals move through these stages as they initiate a new behavior, but that this 




before behavior change is achieved (Prochaska et al., 2008). As individuals move 
forward, individuals increase their self-efficacy in managing health decisions while 
adopting positive health behaviors (Wiley et al., 2000). 
  Studies have suggested that individuals’ self-efficacy and decisional balance are 
major influences on medication and health care utilization (Hibbard, Mahoney, Stock, & 
Tusler, 2007; Johnson et al., 2006a; Johnson et al., 2006b).  Self-efficacy comprises two 
interrelated components: self-confidence, the ability to make and sustain changes; and 
temptation, the impulse to relapse to a former stage (Johnson et al., 2006b).  As the 
individual builds self-efficacy, the individual's decisional balance has a positive shift 
forward, propelling the individual to the next stage (Prochaska et al., 2008).  Increasing 
self-efficacy is important to maintaining a new behavior.  
Behavior results from the interaction of three distinct factors (also known as 
triadic factors), personal, behavior, and environment (Zimmerman, 1989).  Self-efficacy 
is part of a self-regulatory process related to how individuals use and combine the triadic 
factors in an attempt to achieve a specific goal or behavior (Clark & Dodge, 1999).  
Drawing from personal factors (information and beliefs), environmental (e.g., advice 
from experts, role models) and one’s own behavior to make a decision to attempt a new 
behavior (e.g., starting a new medication).  If the trial of starting a new medication and 
outcomes are successful, then another attempt is made.  Individuals with greater self-
efficacy, have a greater likelihood of repeating new behaviors than individuals with lower 
self-efficacy (Clark & Dodge, 1999).  Patients who maintain new behaviors are predicted 




A significant problem in effecting long-term change is that feelings of self-
efficacy for some behaviors may diminish over time.  This lack of self-efficacy may, in 
turn, translate into negative changes of behavior, health status, and self-medication 
management (Lorig & Holman, 2003), which are particularly prevalent in older adults 
with chronic diseases (Johnson et al., 2006a; Lee, Grace, & Taylor, 2006).  Treating 
chronic diseases is limited by barriers that challenge older adults, reducing their self-
efficacy and self-management, leading to nonadherent behavior (Lee, Grace, & Taylor, 
2006).  This study specifically investigated the effectiveness of pharmacists using 
telephone or face-to-face services to assist patients in overcoming these barriers to 
adherence.  
In SOC theory’s precontemplation stage, an individual has no serious thought 
about changing or initiating a new behavior.  At this stage, an individual’s self-efficacy 
and management skills are insufficient to initiate any behavior changes, rendering many 
individuals frustrated, or discouraged (Berger & Grimley, 1997).  This lack of self-
efficacy also manifests in a lack of individuals’ awareness that they must be active 
participants in their own health care (Hibbard, Mahoney, Stock, & Tusler, 2007).  There 
is a positive correlation between self-efficacy, management skills, and health care 
engagement (Barlow, Wright, Sheasby, Turner & Hainsworth, 2001; Hibbard, Mahoney, 
Stock, & Tusler, 2007). 
In the contemplation stage, an individual gives serious thought to behavior 
change.  Individuals at this stage are usually medication nonadherent because they lack a 




may also be experiencing various types of barriers such as medication side effects, health 
beliefs, finances, and medication complexity (Hibbard et al., 2007; Konkle-Parker, 2001).  
Pharmacists may be instrumental moving the patient to the next stage by educating the 
patient and removing the environmental barriers. 
Preparation is the stage where individuals may have taken some steps already by 
setting a date when to start their new medication.  The individual’s self-efficacy and self-
management skills have improved but may not be sufficient to initiate a new behavior 
(Fick & Farris, 2005).  Any nonadherence problem would be most likely unintentional.  
At this stage, pharmacists would encourage patients to associate taking their medication 
with a daily event or events (Fick & Harris, 2005).  Success at this stage is seen when 
strategies are used to enhance commitment.   
In the action stage, behavior change has taken place; however, individuals may 
become nonadherent because of unresolved issues because of the medication, or they 
may be experiencing other health problems (Fick & Harris, 2005).  Individuals may lack 
necessary social or community support needed to continue the new behavior.  Follow-up 
phone calls from a pharmacist to resolve any residue medications issues would assure the 
success of the patient to move to the next stage (Konkle-Parker, 2001).  Therefore, any 
interventions in this stage should be geared toward supporting the new behavior. 
In the maintenance and termination stage, the new behavior is now more than 6 
months old and the individual has sufficient self-efficacy and management skills to 




consistently adherent to their medications.  Pharmacists need to be vigilant concerning 
medication refill patterns and intervene as needed.  
Konkle-Parker (2001) identified four different types of factors relating to 
medication adherence: 
1.  Medication related: medication side effects, regimen complexity, size and 
taste of medication, dietary restriction, and duration of treatment regimen.   
2.  Client related: health literacy level, health beliefs, health status, self-
efficacy, and medication self-management.   
3.  Provider related: relationship with physician, appointment frequency, and 
communication skills with provider.  
4.  Environmental: finances, transportation, and social support.   
Pharmacists’ skills and interventions differ from one stage to another stage 
depending upon the medication adherence factors (Ficke & Farris, 2005; Konkle-Parker, 
2001).  In the precontemplation stage, the pharmacist experiences more client and 
provider related factors.  In the contemplation, preparation, or action stage, the majority 
of factors are medication related and some client- or provider-related factors (Konkle-
Parker, 2001).  Improving adherence is difficult, and the key for the pharmacist is to 
move the individual one stage at a time for optimal success (Berger & Grimley, 1997; 
Prochaska et al., 2008).  Patient’s self-efficacy is improved when barriers to medication 





Medication adherence is one of the most intriguing and complex behaviors 
demonstrated by patients (Hughes, 2004).  Adherence is influenced by many social and 
behavioral factors and is significant in influencing treatment outcomes (Brown & Bussell, 
2011; Martin, Williams, Haskard, & DiMatteo, 2005).  Poor adherence can render the 
best treatment ineffective and continues to be a source of frustration to health care 
professionals (Osterberg & Blaschke, 2005).  Numerous efforts have been undertaken to 
change the current findings of medication adherence 
Medication nonadherence is a widely acknowledged and a pervasive problem that 
involves all health care providers.  A key to proper chronic disease management is being 
adherent; yet nonadherence is observed in approximately 50% to 55% of older adults (≥ 
65 years) with chronic conditions (Doggrell, 2010; Lehane & McCarthy, 2006).  This 
population is exemplified by multiple chronic conditions, requiring complex medication 
therapy and compounded by cognitive deficits, low health literacy, and inadequate oral 
and written communication skills (Hughes, 2004; Ngoh, 2009).  Poor disease 
management may represent a greater risk for older adults due to multiple co-morbidities 
and medication complexity. 
Although the terms compliance and adherence are often interchangeable 
compliance is associated with a more passive behavior where the individual agrees with 
the physician’s advice but the individual is not fully engaged with treatment (Osterberg & 
Blaschke, 2005).  Being adherent, the individual is more actively engaged and in accord 




2003).  Being adherent implies that there is cooperation and an established relationship 
between the health care team and patient (collaborative care).  Adherent behavior for 
chronic diseases dictates self-management, an individual’s ability to take prescribed 
medication appropriately, filling the prescribed medication, scheduling and attending 
follow-up appointments, and having the self-efficacy to manage therapeutic behaviors 
(Lorig & Holman, 2003;WHO, 2003).  The focus of effective treatment adherence is 
based on not only actions of health professionals but equally and more importantly by the 
patients themselves.  The more actively engaged patients are with their health care 
provider and in their own health care, the more successful they are in their self-
management skills (Barlow et al., 2002; Hibbard & Cunningham, 2008).  An adherent 
patient is actively engaged, making daily decisions that affect their health and costs 
(Hibbard & Greene, 2013).  Ultimately, the level of adherence correlates with patient 
engagement. 
Medication complexity has been implicated in undermining effective chronic 
disease management leading to poor medication management.  Choudhry et al. (2011) 
studied the relationship of therapeutic complexity on adherence and chronic disease (e.g., 
cardiovascular disease).  This large retrospective cohort study used data prescription 
claims from 1,827,395 patients.  The mean age of the patient was 63 years.  Therapeutic 
complexity was defined as the total number of prescriptions, number of fills for 
medications in different drug classes and for maintenance use, the number of physicians 
who wrote the prescriptions, the total number of pharmacies, and number of different 




consolidation of these refills.  The Choudhry et al. (2011) study results highlighted 
complexity but also implicated variables such as multiple trips to pharmacies and 
multiple physicians, which added to medication nonadherence. 
Nonadherence is divided into intentional nonadherence (active and reasoned 
decision process) and unintentional nonadherence (passive process) (Lehane & 
McCarthy, 2006).  Lehane and McCarthy (2006) identified unintentional medication 
nonadherence with three key factors: (a) drug (medication scheduling, drug regimen, 
drug side effects, and packaging); (b) patient (age and changing physiology, multiple 
comorbidities, cognitive ability, health literacy and personal beliefs); and (c) health-
system (patient-provider relationship, medication access, and social support).  Intentional 
nonadherence correlates to patients’ beliefs in accepting or disregarding professional 
advice (Lehane & McCarthy, 2006).  Unintentional and intentional factors are important 
when considering medication complexity and the influences over maintenance 
medication adherence. 
From an economic standpoint, nonadherence to medication regimens can be 
costly, as poorly controlled chronic conditions can require additional medical therapy, 
increases in medical provider office visits, and nonscheduled hospitalizations resulting 
from drug-related adverse effects (Ho et al., 2006; Hughes, 2004; Mahoney, Ansell, 
Fleming, & Butterworth, 2008).  The New England Healthcare Institute (2009) estimated 
that $290 billion per year or 13% of total health care is due to intentional and/or 





Roebuck et al. (2011) compared medication adherence of four chronic disease 
states (heart failure, hypertension, T2DM, and dyslipidemia) to health care costs in a 
retrospective cohort study of 135,008 patients.  The analysis included three measures of 
health services use: inpatient hospital days, emergency department visits, and outpatient 
physician visits.  Across all conditions, there was a positive correlation between annual 
inpatient hospital days and adherence, ranging from six fewer days for older adults with 
heart failure to one fewer day for those with dyslipidemia.  Finally, there was a reduction 
in emergency visits and increase in physician visits in the more adherent patients.  
Medication nonadherence is a complex problem involving many factors; 
therefore, optimizing drug therapy outcomes needs a multipronged approach.  Patient 
health outcomes have shown improvement when patients are encouraged to take a more 
active role in their health care (Coulter & Ellins, 2007).  There is a positive correlation 
between increased patient's self-efficacy with treatment and medication management and 
use of services and cost (Evangelista & Shinnich, 2008; Osterberg & Blaschke, 2005).  
Collaborative drug therapy management by various health care providers (pharmacists, 
physicians, and other allied health professionals) in accordance with the patient became a 
viable solution to maximize the patient’s health-related quality of life.  The pharmacist 
would share the responsibility for patient outcomes.  To assume this level of 
responsibility, the pharmacist’s role needs to shift from purely pharmaceutical dispensing 
to more of a clinical role, where the pharmacist takes a more active role in drug 




2012).  Pharmacists must now focus on patient and drug safety and develop relationships 
with other health care providers.  
Pharmaceutical Care 
Pressure from policy makers, along with other factors, influenced the pharmacy 
profession to undergo a number of substantial changes to increase the professions’ 
responsibility to reduce preventable drug-related morbidity and mortality (Carmichael et 
al., 1997).  During the 1990s both community and hospital pharmacists moved away from 
a more traditional pharmaceutical dispensing role to a pharmaceutical care model as 
drug-related problems (DRPs) were recognized as serious and urgent (Berenguer, 
LaCasa, de la Matta, & Martin-Calero, 2004; Chewning, 1997; Helper & Strand, 1990).  
This new model involved enhanced clinical skills of the pharmacist (drug therapy 
monitoring, patient counseling and drug information services) and increased patient 
engagement with their own care (Chewning, 1997).  In the pharmaceutical care model, 
pharmacists provided services such drug therapy medication management: identifying 
problems, implementing solutions, monitoring outcomes.  The desired outcomes were to 
optimize the benefits of an individual’s pharmacotherapy and to improve the quality of 
life.  
At this same time, policy makers included pharmaceutical care in the 1990 
Omnibus Budget Reconciliation Act (OBRA 1990) (Fulda & Hass, 1992).  OBRA 1990 
was enacted to assist in reducing the U.S. federal budget deficit.  OBRA 1990 also was 
instrumental in creating the Drug Utilization Review (DUR) boards (Fink, 2008).  State 




such as Medicaid, injured workers, and state employee benefits (Fink, 2008).  OBRA 
1990 was also responsible for requiring pharmacists to counsel all patients receiving 
prescriptions.  Pharmacists addressed items such as name of drug, intended use and 
therapeutic outcomes, side effects, proper storage, possible drug to drug or drug to food 
interactions, and any needed action in the case of a missed dose.  Although originally 
designed to assist Medicaid recipients with understanding their medications, this act was 
quickly extended to all patients receiving prescriptions (Fink, 2008).  OBRA 1990 was 
the government’s comprehensive piece of legislation on medication process and drug and 
patient safety. 
Another approach to preventing drug-related problems involves having 
pharmacists directly involved with monitoring drug treatments.  In a community clinic 
and hospital settings, pharmacists monitored the effectiveness of medications by 
performing blood pressure, glucose, and cholesterol checks (Berenger et al., 2004).  
Studies have shown improved patient outcomes with chronic conditions such as heart 
disease, T2DM, hyperlipidemia when pharmacists increased patient engagement in their 
own health care (Bluml, McKenney, & Cziraky, 2000; Cranor, Bunting, & Christensen, 
2003; Fischer et al., 2000).  Fischer et al. (2000), using a quasi-experimental design, 
investigated if using pharmaceutical care services had beneficial effects on chronic 
diseases.  The priori consisted of health management organization (HMO) enrollees 
(average age of 63 years) being treated for a chronic condition (asthma, COPD, or heart 
disease).  The intervention group received pharmaceutical care with their prescriptions, 




intensive counseling, education regarding medications, and regular monitoring.  Fischer 
et al. (2000) demonstrated that pharmaceutical care increased self-medication 
management skills and awareness of medication side effects. 
Community pharmacists were in an exceptional position to offer pharmaceutical 
care services.  Community pharmacists could review prescriptions for age 
appropriateness, medical conditions, and concurrent medications.  With their increased 
availability, pharmacists were available to counsel patients on medication, and stress the 
importance of medication adherence.  Many times, it was the pharmacist who the patient 
saw last prior to their medication being taken.  Although many pharmacists at the retail 
level openly embraced this new pharmaceutical care model (Berenguer et al., 2004) 
researchers have shown that pharmacist-patient communication interaction at the 
community level was less than optimal (Devraj & Gupchup, 2011; Flynn, Barker, Berger, 
Lloyd, & Brackett, 2009; Swarstad, Bultman, & Mount, 2004).  Patient education is a 
vital intervention for older adults to be medication adherent. 
Given the importance of providing clinical support to patients receiving 
medication, and that this may not be happening at the retail setting, telephonic 
communication could be a viable alternative venue for the pharmacist and the patient.  
Older adults are especially vulnerable to medication nonadherence when faced with a 
new diagnosis and medication treatment plan, and not being fully engaged in treatment 
(NCPIE, 2007).  Disease progression with complications and decreased quality of life has 
been correlated with medication nonadherence (Hughes, 2004; Roebuck, Liberman, 




Yang et al., 2009).  Telephone management by pharmacists was shown to be appropriate 
for many chronic conditions (Car & Sheikh, 2003; Dolder & Dolder, 2010; Rickles, 
Svarstad, Statz-Paynter, Taylor, & Kobak, 2005; Walker et al., 2011; Ward & Xu, 2011; 
Wu et al., 2006).  In patients receiving antidepressant treatment where nonadherence is 
relatively high within the first 3 months, patient receiving telephonic support increased 
medication adherence and improved clinical outcomes (Rickles et al., 2005).   
Hospital discharge can be stressful especially for the older adult, as the patient 
transitions to a new environment and then is expected to remember new medication 
instructions.  In a study by Dudas, Bookwalter, Kerr, and Pantilat (2001), follow-up 
phone calls by pharmacists were shown to increase patient medication adherence.  
Chronic conditions such as diabetes and cardiovascular disease have better outcomes 
when treatment levels are at goal.  Using telephonic interventions, pharmacists were 
successful in managing their patients and getting them to their stated goal (Dolder & 
Dolder, 2010; Walker et al., 2011).  Phone-based settings may offer pharmacists and their 
patients a wider variety of opportunities to deliver pharmaceutical care. 
Chronic Disease Management 
As chronic diseases became the dominant leading causes of death, the distinct 
discipline and management of chronic diseases became a focus of public health (Davis, 
Wagner, & Groves, 2000).  The treatment and management of chronic disease often 
changes over time according to fluctuations in patient symptoms and in the disease 
process.  The key to managing chronic disease is to improve both short- and long-term 




Chronic disease management is no longer treating chronic diseases as separate 
disease entities but rather is a team-based direct-patient care approach (Hibbard et al., 
2007; Lorig & Holman, 2003; Norris, Glasgow, Engelgau, O’Conner, & McCulloch, 
2003).  Patients with chronic conditions make daily decisions concerning self-
management (Lorig & Holman, 2003; Norris et al., 2003).  For many, self-management is 
a life-long task.  Clinical management of chronic disease shifted from a focus of 
primarily pharmacologic and technologic intervention, to include patient self-
management behaviors and education with increased clinician-patient interactions (Norris 
et al., 2003).  Pharmacists as members of a team-based approach for patient care saw 
success for meeting patient needs and improving health care quality. 
Self-management programs, in conjunction with provider patient care, empower 
patients to solve personal health-related problems.  The outcome is to increase quality of 
life while living with chronic disease.  As members of a health care team, pharmacists are 
key to providing information on safe, effective, and optimal medication use (Carmichael 
et al., 1997; Patwardhan, Duncan, Murphy, & Pegus, 2012; Rodriguez de Bittner & 
Zaghab, 2011).  In a collaborative care setting, the pharmacist and patient design health 
care decisions together, with the pharmacist assisting the patient with problem-solving 
skills to enhance self-efficacy and medication management (Bodenheimer, Lorig, 
Holman, & Grumbach, 2002).  This collaborative approach would help assure that the 
patient needs would be met with improved health care quality.  Using a pharmaceutical 
care practice, the pharmacist validates the patient-defined problems (Bodenheimer et al., 




Garrett and Bluml (2005) demonstrated that using consultations, clinical goal setting, 
monitoring, and collaborative drug therapy had significant improvements in diabetes 
management including improvement in reaching goals.  Patients had increased 
satisfaction with their diabetes care provided by their pharmacists. 
An example of a chronic disease that warrants close adherence to prescribed 
medications is T2DM.  Type 2 Diabetes Mellitus is the seventh leading cause of death, 
with prevalence of 25.8 million people in the United States (Qaseem, Humphrey, Sweet, 
Starkey, & Shekelle, 2012).  Type 2 Diabetes Mellitus can lead to long-term 
complications such as microvascular, macrovascular, and cardiovascular disease.  
Although medications have been shown to be efficacious in reducing short- and long-
term effects of the disease, treatment goals are often not reached.  Barriers leading to 
treatment goal failure are numerous, but complex medication regimens and convenience 
factors are prevalent for older adults (Nam, Chesla, Stotts, Kroon, & Jansen, 2011, 
Osterberg & Blaschke, 2005).  Provider-defined problems versus patient-defined 
problems have also been implicated in medication nonadherence.  For many patients it is 
more important to avoid the adverse effects of hypoglycemia caused from oral diabetic 
medications happening in the present than the possibility of kidney disease occurring in 
the future (Bodenheimer et al., 2002). 
It is important to understand nonadherence from  patients’ point of view.  It is 
through personal communication that patients’ perceptions of treatment may radically 
differ from that of the prescriber (Grant et al., 2011; Ramalho-de Oliveira, Shoemaker, 




patients’ perceptions differed from those of the treating clinician and ADA guidelines 
(Grant et al., 2011; Ramalho-de Oliveira et al., 2012): 
1.  Medication initiation was viewed as a negative event as it reflected personal 
failure and an added burden.   
2.  Medication intensification was viewed as a risk factor for diabetes-related 
complication.  Patients did not fully understand the disease process and 
progression.  
3.  Patients never voiced a concern regarding a delay in medication changes 
and/or additions.  ADA recommends regular assessments and changes as 
needed (ADA, 2013).  Most patients were focused only on the present and 
not the future.  Patients however, favored individualized medication 
planning (Grant et al., 2011). 
Type 2 Diabetes Mellitus treatment success depends upon medication adherence, 
self-monitoring of blood glucose, nutritional and physical therapy, and frequent 
laboratory and medical appointments (ADA, 2013).  Pharmacy benefit management 
pharmacists have access to a variety of patient medical and laboratory data.  The 
available data assists the pharmacist in looking for warning signs on poor treatment 
adherence.  In the case of diabetes, indicators of poor treatment adherence may include 
blood glucose readings and blood pressure not at acceptable levels, erratic office visits, 
weight gain, and dietary and medication nonadherence (Dang, 2013).  Patients with 
T2DM require a comprehensive treatment plan specially tailored to their needs, as 




pharmacists are in a perfect position through telephone consulting to use communication 
interventions to increase patient adherence and improve communication with a primary 
care provider. 
There is no ideal method to improve medication adherence.  Today’s PBMs have 
innovative programs that plan sponsors can use to help maintain the overall health of  
company employees (Lawrence, Qu, & Briskin, 2012).  Specific to this current study, 
T2DM is a chronic condition that is a focus of MTM programs used to educate 
customers.  Currently, through personal communication with the patient, MTM 
pharmacists play a key role by creating personalized therapy that takes into account the 
patient’s specific attitudes and concerns about their medication regimen, as well as their 
lifestyle factors (Lawrence et al., 2012.).  
Pharmacy Benefit Managers 
Pharmacy benefit managers are independent arms of many health plans whose 
function is to reduce health plan prescription-drug costs while maintaining high quality 
prescription-drug delivery and patient care (Lawrence et al., 2012).  Pharmacy benefit 
management companies manage the prescription drug plans for health insurance issuers 
and plan sponsors (PCMA, 2003; Shrank et al., 2009).  Pharmacy benefit managers create 
provider networks of pharmacies and inter-related services for the health plans.  While 
some PBMs operate as independent entities selling PBM services to multiple types of 
health plans, other PBMs are wholly owned by the health plan (PCMA, 2003).  Whether 





When Congress voted to expand the Medicare drug benefit to include outpatient 
medication coverage, the overarching problem was how to pay, administer the benefits, 
and use cost containment measures (Huskamp, Rosenthal, Frank, & Newhouse, 2000).  
Congress received a number of different proposals with a common thread of allowing 
PBMs as the administering agent to employ a PBM model for these Medicare programs 
(Lawrence et al., 2012).  Although the current PBMs were successful in reducing 
pharmacy costs and increasing net savings with Medicaid programs in various states, 
prescription drug costs are still on the rise (Lawrence et al., 2012). 
Pharmacy benefit managers have not always been known for their clinical 
services but have been judged largely on their cost-saving methods (Mullins & Wang, 
2002; Shrank et al., 2009).  However, factors such as new expensive drugs, greater 
utilization of prescription drugs, the aging baby boom generation, and direct-to-consumer 
marketing all gave rise to increasing prescription drug prices (Garis, Clark, Siracuse, & 
Makoid, 2004).  It was necessary for PBMs to design and integrate innovative programs 
that would address these issues.   
In order to increase health outcomes and still continue to curb health care 
spending, PBMs needed to produce a more cost-effective pharmaceutical care system 
(Shrank et al., 2009).  Pharmacy benefit managers underwent a clinical process redesign, 
integrating pharmaceutical care into clinical pharmacy services and medical services 
across locations (Mullins & Wand, 2002; Shrank et al., 2007).  Studies have shown that 
multifactorial interventions that include better medication systems, education, and 




2002; Chodosh et al., 2005; Inzucchi et al., 2012; Kripalani, Yao, & Haynes, 2007; 
Osterberg & Blaschke, 2005).  With the use of electronic data, PBM MTM clinical 
pharmacists via the telephone can provide not only the essential counseling and patient 
education as mandated by the Centers for Medicare and Medicaid Services (CMS) but 
can also perform screenings and assessments (Moczygemba et al., 2008; Shrank et al., 
2007).  Essentially, electronic data have allowed pharmacists to assist patients with a 
variety of nonadherence issues and bridge patient-physician communication gaps. 
Pharmaceutical care services, later known as DM services, expanded PBM 
pharmacists roles from mainly cost savings to covering safety, medication adherence, 
educational, behavioral, and informational resources leading to increased quality of care 
(Lawrence et al., 2012; PCMA, 2003).  Clinical pharmacists proved to be well suited for 
medication management due to their expertise on medication use and specialized training 
on specific diseases (Sipkoff, 2007).  Pharmacists running DM programs, including 
MTM programs, were proving to be successful in the treatment of chronic diseases and 
increasing therapeutic outcomes.  By directly engaging the patient, PBM pharmacists 
could reduce any perceived barriers and increase adherence and health outcomes 
(Oladapo & Rascati, 2012; Shrank et al., 2009).  
The Centers for Medicare and Medicaid Services allowed MTM services to be 
delivered via face-to-face interventions, telephone consultations, and educational mail 
campaigns.  Feifer et al. (2010) found medication adherence increased when there was 
telephone support by a clinical pharmacist soon after filling with a new prescription.  




back to their medical provider for any new problems and fewer patients returned to the 
emergency room compared to the non-phone follow-up group (Feifer et al., 2010).  
Pharmacy benefit managers offering full services found that incorporating telephone 
MTM services could provide patient specific care resulting in improved health outcomes 
(Moczygemba et al., 2008).  Medication therapy management services were effective in 
increasing patients self-management skills and medication adherence. 
Health Care in the United States Prior to MMA 2003 
Despite the positive contributions by the pharmacy profession over the years, 
there remained concerns about patient safety, drug therapy, and the quality of health care.  
Studies howed that the costs of adverse drug events (ADEs) exceeded the initial cost of 
medications (Ernst & Grizzle, 2001; Smith, 1993; Sullivan, Krelig, & Hazlet, 1990).  
ADEs, inappropriate medications, and medication nonadherence were responsible for 
increased rates of hospitalization (Brennan et al., 1991; Chutka, Takahashi, & Hoel, 
2004; Fick, Nion, Beers, & Waller, 2008; Leape et al., 1991; Page & Ruscin, 2006).  In a 
large retrospective study of 11,500 patients with diabetes mellitus, nonadherence 
accounted for 20% of the patients and was associated with elevated hemoglycolated 
blood levels, blood pressure and lipid blood levels.  Nonadherent patients had significant 
risk for all-cause hospitalization and mortality (Ho et al., 2006a).  Primary prevention is 
crucial in treating and preventing future adverse events in T2DM. 
Inappropriate drug prescribing to older adults continued to be a major concern as 
it contributes to drug-related morbidity and mortality.  Inappropriate medications are 




medication benefits placing older adults at great risk for adverse events.  In a 
retrospective small study of 390 patients, Page and Ruscin (2006) reported that 107 
patients were prescribed an inappropriate drug, and 124 patients experienced ADEs.  Fick 
et al. (2008), in a large retrospective study of approximately 18,000 older adults, 
identified 6,875 individuals (40%) with one inappropriate medication and 2,326 older 
adults (13%) with 2 or more inappropriate medications.  The Fick et al. (2008) findings 
illustrated that inappropriate medication in the older adult can lead to ADEs, falls, and 
injuries, leading to a poorer quality of life. 
Nonadherence can be due to skipping, reducing the dose, or not filling the 
prescription.  In a 2-year time span prior to the enactment of MMA 2003, it was 
estimated that approximately two million Medicare beneficiaries were medication non-
adherent due to cost (Mojtabal & Olfson, 2003).  Medication nonadherence was highest 
among enrollees who had no or partial medication coverage.  In a national survey of 
approximately 17,600 Medicare beneficiaries prior to the enactment of the Medicare drug 
benefit, 25% (4,400) of the enrollees reported medication nonadherence of one important 
medication due to cost (Safran et al., 2005; Soumerai et al., 2006).  Approximately 50% 
(8,000) reported giving up basic necessities and groceries to be able to afford their 
medications (Safran et al., 2005). 
Older age is significant as an independent variable for adverse drug reactions 
leading to hospital admissions.  Older age is positively correlated to frailty, multiple 
comorbid conditions, and polypharmacy, leading to hospitalizations second to ADEs 




frequency of ADEs among 30,000 Medicare beneficiaries in an ambulatory setting.  
Amongst 1,523 identifiable ADEs, 421 (28%) were considered preventable, and 578 
(38%) were identified and classified as serious, life threatening, or fatal.  In a national 
surveillance of emergency department visits, older adults had the highest percentage of 
ADEs and second highest of ADEs leading to hospitalizations (Budnitz et al., 2006). 
Hospital admission was higher for individuals 75 years and older (11%) compared to 
individuals 65 years and older (26%) (Doggrell, 2010).  Drug-related problems and ADEs 
are a prevalent problem seen in older adults with polypharmacy. 
The overarching message from reviews of health care in the United States is that 
there were large gaps between those individuals who were receiving care and the care 
these individuals were receiving (McGlynn et al., 2003; Schuster, McGlynn, & Brook, 
1998).  Gaps in care were seen in all levels of care, from acute to preventative and 
chronic.  Overall, individuals only received 50% of the recommended interventions that 
were involved in their care (McGlynn et al., 2003).  For older adults, only 60% received 
the needed care for chronic conditions (McGlynn et al., 2003).  It was estimated prior to 
2003, that only 64% of older adults received the needed preventative vaccines, 38% 
received preventative cancer screenings and 25% did not have prescription drug coverage 
(McGlynn, et al., 2003; Schuster, McGlynn, & Brook, 1998; Steinbrook, 2002).  The 
quality of medical care for the older adult falls short of acceptable levels for a variety of 
conditions important to this vulnerable subpopulation.  
There were also a lack of structured programs and outpatient medical providers to 




fragmented care led to increased chances for ADEs and poor adherence to treatment 
plans (Smith, Catellier, Conlisk, & Upchurch, 2006).  It was evident to policy makers that 
newer approaches were needed to improve the quality of care and optimize health 
outcomes of all adults (IOM, 2000).  The enactment of the MMA was a national 
milestone to improve health care and improve accessibility to prescription drug care to 
older adults and individuals living with disabilities (Smith, Catellier, Conlisk, & 
Upchurch, 2006). 
The MMA of 2003 
In 2002, the aggregate health care spending in the United States reached in all- 
time high of $1.6 trillion (Levit et al., 2004).  Retail prescription drug sales accounted for 
the largest increase in health care spending, reaching approximately $163 billion (Levit et 
al., 2004).  The current Medicare package did not include coverage for outpatient 
prescription costs, leaving older adults to garner continuously the resources needed to 
purchase medications and proper health care or do without some essentials (Mojtabel & 
Olfson, 2003). 
In a landslide move by policy makers, the MMA brought Medicare beneficiaries 
health care and prescription benefits that would be consistent with those offered to 
working-age Americans (Mojtabel & Olfson, 2003).  Initiated in 2006, older adults and 
individuals with disabilities could purchase a prescription drug plan (PDP) through a 
benefit designated as Part D (optional drug benefit for Medicare beneficiaries who remain 
in traditional Medicare Parts A or B) or as part of the Medicare Advantage program (Ma-




The new law also required the plan sponsors offering PDPs or Ma-PD to offer 
Medicare beneficiaries a new program called MTM.  The CMS had expectations that 
MTM services would improve drug therapy and medication adherence while reducing 
prescription costs for older adults.  Originally, CMS offered little guidance on the 
parameters of the MTM programs and did not mandate the involvement of a pharmacist; 
however, the CDC officially recognized the clinical experience of pharmacists as 
providers and that they receive compensation for MTM services (Centers for Medicare 
and Medicaid, 2005).  Today, the vast majority of MTM programs use pharmacists to 
provide this service as pharmacists are the ideal health care professional based on their 
knowledge of drug therapy and accessibility to patients in the community (McGivney et 
al., 2007; Shoemaker & Hassol, 2011). 
 
Disease Management Therapy 
With the adoption of MMA in 2003, a voluntary (also called opt-in) prescription 
drug benefit program was offerred to all Medicare eligible recipients via the Medicare 
Part D program.  To help with the perverse problem of ADEs and poor medication 
adherence in older adults at risk, MMA 2003 required that insurers provide an MTM 
program (Meyer & Cantwell, 2004).  At-risk older adults are noted for numerouse 
chronic conditions, multiple medications, and physicians, leading to an increased risk for 
adverse events.  For effective health care and positive outcomes for the patient, health 
information needs to be shared, and patient care must be a coordinated effort by all 




Services required that MTM would be distinct from other currently offered programs 
(Pellegrino, Martin, Tilton, & Touchette, 2009).  Medicatuion therapy management 
programs would be based on collaborative care and be patient centered. 
Pharmacy practice at the retail level under OBRA 1990 required all pharmacists 
to counsel patients about their prescriptions (Fink, 2005).  The inherent problems with 
OBRA 1990 were that the counseling represented a single event at the time of dispensing, 
the patient’s history was not considered, and there was no follow-up by the pharmacist or 
other providers to to ensure patient adherence (Pellegrino et al., 2009).  Essentially, 
patient counseling used to be a one-way conversation from pharmacist to patient, follow-
up responsibility was placed upon the patient, and there was lack of patient engagement 
in their medication management.  Pharmacists now need to use patient counseling as a 
tool to ensure that patients have the needed information to take a specific medication 
properly (McGivney, 2007). 
Disease management programs were adopted by many organizations in the 1990s 
as patients with chronic diseases needed the coordinated efforts of various health care 
providors where patient-self efficacy and engagement was significant (McGivney et al., 
2007).  Many programs included physicians, nurses, nutritionists, and pharmacists.  The 
key objectives of DM were to focus on a single specific disease, provide patient 
education, and increase patient self-efficacy and engagement in self care (McGivney et 
al., 2007).  These programs were instrumental in meeting a variety of patient drug and 
disease specific needs.  Pharmacist managed disease state programs included 




robust in meeting the patients disease stated goals, and decreasing hospital admissions 
and mortality (Chisholm-Burns et al., 2010; Chodosh et al., 2005).  The success of these 
programs were due to the two-way conversations between pharmacist and patient and 
then follow-up to provider to create solutions to drug therapy problems.  The main 
drawback to DM programs was that the provided tools and education were limited to that 
individual disease state.  
Medication Therapy Management Services 
The Centers for Medicare and Medicaid Services required three core outcomes to 
their new program: (a) optimize patient therapeutic outcomes, (b) improve medication 
adherence, and (c) detect and decrease ADEs and improper prescription medication use 
(Pellegrino et al., 2009).  With limited outcomes available on MTM services and to 
encourage innovations and competition by pharmacy and other health care organizations, 
the CDC did not clearly define all MTM activities and service provisions to achieve these 
outcomes (Pellegrino et al., 2009).  However, these services were to be developed as a 
collaborative effort between pharmacists and physicians.  More than 25 leaders 
representing PBMs, health plans, health care organizations, and state and national 
pharmacies constructed a consensus definition of MTM services (Curtiss, 2005; 
Pellegrino et al., 2009). 
Driven by the philosophy of pharmaceutical care, two major frameworks were 
developed from the consensus definition.  The frameworks were viewed as a 




MTM frameworks incorporate patient counseling, motivational interviewing, patient 
assessment and education, documentation, and collaborative care (McGivney, 2007). 
The American Pharmacist Association and the National Association of Chain 
Drug Stores Foundation developed a framework representing the community 
pharmacists.  This platform focused on providing greater detail on the rationale and 
procedures for the core outcomes as specified by the CMS (Pellegrino et al., 2009).  
Operationally, this platform is for a face-to-face interaction; however, other routes 
(home-visits or telephonic) are acceptable. 
The Academy of Managed Care Pharmacy (AMCP) developed a framework 
representing managed care and PBM pharmacies.  This platform, focusing from an  
insurers’ perspective, places greater detail on coordination of care, outcomes assessment, 
patient identification, and collaborative care with other heath care providers. 
Operationally, this platform is telephonic; however other routes (face-to-face or home- 
visits) are acceptable if supported by evidence (Pellegrino et al., 2009). 
Medication therapy management service is distinct from the mandated counseling 
that occurs as a result of OBRA 1990 and is more comprehensive than DM programs.  
Specifically, MTM service has the following characteristics: 
1.  It is patient-centered rather than product-centered.  The pharmacist 
considers each individual as unique, not only in how patients experience and 
understand their medical conditions, but also in their personal values and 
beliefs in regard to their care and treatment (Ramalho-de Oliveira, 




improved with an increased understanding of their disease, and the 
perceived need for treatment and their medications (Maclaughlin et al., 
2005).  A patient’s attitudes or concerns toward medication therapy will 
vary from patient to patient and are often the basis of drug therapy 
nonadherence.  To resolve and prevent drug therapy problems, the 
pharmacist needs to comprehend the patient’s medication experience.  Only 
after understanding the patient’s motivations and the root of their attitudes 
and decisions can the pharmacist assist the patient with the process of 
behavorial change, when warranted (Ramalho-de Oliveira et al., 2012).  
This is a key issue when treatment is targeted toward prophylaxis or 
asymptomatic treatment.   
2.  Pharmacists focus on the patients total medication experience and not just 
one from a particular disease state. 
3.  Pharmacist-patient communication empowers the patient and increases 
patient engagement in managing their own medications and health care 
(Sieckler, 2010).  Low health literacy, self-efficacy, and medication 
complexity are factors that have been repeately recognized that impact 
medication adherence.  Having low health literacy may impede a patient’s 
ability to correctly intrepret their clinician’s verbal and written instructions.  
Other studies have found that low health literacy was associated with an 
inability to read and comprehend prescription labels or correctly navigate 




MacLaughlin et al., 2005).  Being medication adherent is more than just 
taking medication, but is a complex process for the patient and healthcare 
provider. 
Service Delivery Mode 
CMS did not specify regarding whether MTM should be provided face-to-face, 
telephonically, mailed interventions, or combinations (Pellegrino et al., 2009).  Face-to-
face MTM services may be performed at various different locations, as long as the 
medication evaluation can be conducted in a private area (Shoemaker & Hassol, 2011).  
Such MTM settings may include community pharmacy settings, ambulatory clinics, 
institutional pharmacy practice, private  pharmacy consulting services, or other areas 
where there is a private area for the pharmacist-patient meeting (Shoemaker & Hassol, 
2011).  The Academy of Managed Care Pharmacy uses a combination of telephone and 
mail, where interventions are mailed to both patients and providers.  As MTM programs 
have evolved, telephonic based services have increased in popularity as telephonic 
services could be provided in the privacy of the patient’s home, provide patient-specific 
care and be more accessible to Medicare beneficiaries with travel logistic problems 
(Academy of Managed Care Pharmacy, 2008; Moczygemba, Barner, Gabrillo, & Godley, 
2011; Shoemaker & Hassol, 2011).  Medication Therapy Management telephonic 
services were an efficient solution for government and private insurers to reach MTM 
program eligible members.  
While many community and clinic setting pharmacists found MTM rewarding, 




barriers have included time and staff management logistics, reimbursement issues 
(individual fee-for-service), patients’ lack of interest, and lack of access to patient records 
(Dolor et al., 2012; Lounsbery, Green, Bennett, & Pedersen, 2009; McGivney et al., 
2007; Oladapo & Rascati, 2012).  According to CMS MTM guidelines, MTM services 
are considered as an administrative cost (Moczygemba et al., 2008).  Health plans 
providing telephonic MTM services incorporate this cost into the Medicare Part D plan 
premium rather than having to bill for individual fee for service (Moczygemba et al., 
2008).  By incorporating administrative costs within the MTM program itself, 
government and health plans found a successful solution to reduce a barrier for MTM 
implementation. 
Patients’ Perceptions of Pharmacists as MTM Service Providers  
The success of the MTM program was dependent upon two factors.  The first 
factor was the new role of the pharmacist, from the traditional dispensing model to a 
clinician model.  The second factor was the acceptance of the pharmacist in this new role 
by the patients and will the patients have the same trust (Hong, Liu, Wang, Brown, & 
White-Means, 2011; Moczgemba et al., 2010; Pellegrino et al., 2009).  Patients have 
always viewed the community pharmacist in the more traditional dispensing role rather 
than in a clinical role (Law, Okamoto, & Brock, 2008).   
Patients in general have found the pharmacist providing the MTM services as a 
useful resource, and the information and type of service very important (Hong et al., 
2011; Moczgemba et al., 2010).  Several researchers found a positive association in the 




the pharmacist and improve medication adherence (Doucette, Witry, Alkhateeb, Farris, & 
Urmie, 2007; Lauffenburger, Vu, Burkhart, Weinberger, & Roth, 2012; Law, Okamoto, 
& Brock, 2008; Truong, Layson-Wolf, Rodriguez de Bittner, Owen, & Haupt, 2009).  
Garcia et al. (2009) reported that patients did perceive some barriers to receiving MTM 
services at the retail level.  Barriers included location, parking, time of day/ week, and 
fear that the recommendations may be contrary to their physicians plan of care (Garcia, 
Snyder, McGrath, Smith, & McGivney, 2009).  As more private insurance companies and 
government turned to using a telephonic platform for MTM programs, many patient 
challenges were resolved. 
Measuring Adherence 
Never before has the American population included so many older adults using 
Medicare Part D drug benefits, increasing the importance of medications in the treatment 
of chronic diseases (Kaiser Family Foundation, 2010; NEHI, 2009).  Nonadherence 
affects not only patients but also insurers, and employers as health care costs significantly 
increase because of disease related complications.  The Congressional Budget Office 
(2010) predicted yearly expenditures on Medicare Part D medications would triple from 
$59 billion in 2010 to an expected $177 billion in 2020.  
One of the most challenging elements of quality improvement is measuring the 
quality of care (Nau, 2009) and providing evidence whether prescription drugs provide 
net economic value to those who pay for health care (Sokol, McGuigan, Verbrugge, & 
Epstein, 2005).  Adherence to medication is vital to quality health care and outcomes.  




observation method, measuring drug blood levels, or using electronic medication 
monitors (Osterberg & Blaschke, 2005).  These direct methods can be labor intensive and 
costly, and can limit the number sample subjects (Hudson, Rahme, Richard, & Pilote, 
2007).  For large populations of patients, health service researchers and pharmacy PBM’s 
use pharmacy retrospective databases (refill claims) to describe medication adherence 
and persistence in chronic diseases (Andrade, Kahler, Frech, & Chan, 2006; Choudhry et 
al., 2009).  None of the methods for measuring adherence are considered as a gold 
standard (Hess, Raebel, Conner, & Malone, 2006).  Two preferred methods of measuring 
adherence and persistence using pharmacy drug refill claims data are (a) medication 
possession ratio (MPR) and, (b) proportion of days covered (PDC) (Choudhry et al., 
2009; Karve et al., 2008, 2009; Nau, 2012).  Karve et al. (2008, 2009) found that MPR 
and PDC had the highest predictive validity for future hospitalizations and have formulas 
in which better adherence corresponds to higher values.  
The MPR and PDC are ratios that reflect the proportion of days during a defined 
time period that a patient had possession of any of the drugs used to treat an illness.  The 
MPR ratio is calculated by the sum of days of medication supplied within a defined time 
span divided by the number of days within that period (Nau, 2012).  Although easy to 
calculate, this method has come under scrutiny for its propensity to overestimate the true 
rate of medication adherence as the numerator and denominator have been operationally 
defined in different ways (Peterson et al., 2007). 
The PDC is a newer method of calculating adherence.  Proportion of days 




supply for each fill of a prescription (Nau, 2009).  Yet PDC is more than a simple 
summation of the days’ supplies (Nau, 2012).  In a comparative study, PDC provided a 
more conservative estimate of adherence when patients were using dual therapy in a class 
of drugs or switched to another drug from the same class of drugs (Martin et al., 2009).  
This occurs frequently with antipsychotic and oral hypoglycemic medications. 
Whether using MPR or PDC, the ratios are always between 0 and 1 and may be 
represented by a percentage (ratio multiplied by 100).  A MPR or PDC percentage of ≥ 
80% or ratio of ≥ 0.80 is the industry standard acceptance for adherence (Osterberg & 
Blaschke, 2005).  Performance measures such as MPR or PDC, when used to report 
adherence rates of patients, the reported adherence rate reflects the percent of patients 
who achieved the acceptable industry standard of adherence to the target class of drugs 
(Nau, 2012).  
Treatment adherence is key to better control of chronic conditions and is 
associated with decreased emergency department visits, and hospitalization rates with an 
overall decrease in morbidity and mortality (Roebuck, Liberman, Toyama, & Brennan, 
2011; Yang et al., 2009).  For patients with T2DM taking oral antidiabetic medications, 
antihypertensives, and statin medications, all cause-hospitalization rates were increased 
when adherence rates were < 80% (Ho et al., 2006; Yang et al., 2009).  Lau and Nau 
(2004) found that diabetic patients with adherence rates ≤ 80% were at a higher risk for 
hospitalizations for the following year (odds ratio 2.53; 95% CI 1.38-4.64).  In an 
observational study, Sokol et al. (2005) evaluated the relationships among medication 




disease states for which pharmacotherapy plays a key role in treating diabetes, 
hypertension, hyperlipidemia, and heart failure.  Patients who maintained ≥ 80% 
medication adherence had the lowest rates for all cause hospitalization, which offset the 
higher medication costs (Roebuck et al., 2011; Yang et al., 2009).  
Medication Therapy Management Outcomes 
It has always been the responsibility of the physician to ensure appropriate 
treatment and medication adherence for their patients.  With the rise of chronic diseases 
and resulting complex treatments, pharmacists are in a unique position to fill an important 
role in chronic care management (Patwardhan, Duncan, Murphy, & Pegus, 2012).  Older 
adults are at increased risk for ADEs and medication errors due to a greater prevalence of 
chronic diseases, increased use of maintenance medications and greater dependency than 
younger individuals are (Institute of Medicine, 2000).  Proper treatment of chronic 
diseases includes a variety of different modalities, including patient and life-style 
management and targeted pharmacotherapy taken consistently on a regular basis 
(Rodriguez de Bittner & Zaghab, 2011).  Medication therapy management pharmacists 
are an excellent resource for medication related questions thereby helping patients to 
become more involved with their treatment decisions. 
In a prospective cohort study, Brennan et al. (2012) used MTM service 
recommendations in concordance with both mail order and retail.  Pharmacists assisted 
patients with medication adherence and the initiation of new medication orders.  Patients 
received their medications from a retail location, mail order, or both.  The PBM used 




for the patient and encouraged the initiation of beneficial therapies.  Patient visits and 
calls were documented, and all recommendations were forwarded to the patient’s primary 
provider.  The intervention improved patients’ adherence rates and increased physicians 
initiation rates (Brennan et al., 2012).  
The important issue Brennan et al. (2012) brought to focus is that physicians may 
erroneously assume that patients fill and take all prescribed medications.  This problem 
may further be compounded when physicians make inappropriate medication and dosage 
changes leading to suboptimal health outcomes (Martin, Williams, Haskard, & DiMatteo, 
2005).  Thus, nonadherent patients may suffer from the lack of effective medications and 
risk further complications from the disease.  Specific to this study, I focused on 
medication adherence. 
Using a randomized controlled trial, Planas et al. (2009) evaluated a 9-month 
community-based MTM program on quality of care in hypertensive, T2DM patients. 
Clinical outcomes assessed were blood pressure and medication adherence.  The 
intervention group received MTM services on a monthly basis.  The intervention 
consisted of increasing patient engagement in diet, lifestyle modification, and medication 
management skills.  The control group received counseling on blood pressure at 3, 6, and 
9 months.  All visits were documented and shared with the patient’s primary physician.  
Adherence with medications used in the treatment of hypertension was determined using 
prescription claims data.  At 9 months, the intervention group’s systolic blood pressure 
(SBP) decreased by a mean of 17.32 mm Hg, and the control group SBP increased by 




and at 9 months was 78.8%.  The mean adherence rate of the intervention group prior to 
the study was 80.5% and increased to 87.5% at the end of the study.  The intervention 
group was effective at improving blood pressure and increasing medication adherence 
(Planas, Crosby, Mitchell, & Farmer, 2009). 
Planas et al. (2009) highlighted the importance of the MTM pharmacist as 
medication experts.  The MTM pharmacists were successful in providing patient-centered 
care that resulted in medication adherence and better health outcomes.  Planas et al. 
demonstrated the effectiveness of pharmacists in evaluating patient response to therapy, 
including safety and effectiveness.  As the aging population and incidence of chronic 
disease increases, utilization of pharmacists as medication experts is significant to 
optimal healthcare delivery in the United States.  In the current study, pharmacists as 
medication experts were utilized in conjunction with patients and/or their caregivers to 
promote the safe and effective use of medications and assist patients with medication 
adherence.  The ADA (2013) has documented the growing societal burden of T2DM.  
Medication Therapy Management pharmacists are needed resources to aid patients with 
self-management education and support services to enhance patient understanding and 
appropriate use of medication. 
Although the older adult represents only 13% of the population (USDHHS, 2010), 
the prevalence for drug-related problems is disproportionately large compared with 
younger individuals (Chutka, Takahashi, & Hoel, 2004).  Drug-related problems are 
multifactorial arising most often due to the number of medications, fragmented systems 




seen in the older adult population (Fick et al., 2007).  Older adults have more time that is 
difficult recuperating from acute insults such as ADEs as compared to younger adults 
(Hutchison, 2010).  Multiple ADEs may lead to secondary fragility, increased disability 
and death (Hutchison, 2010).  Budnitz et al. (2006) reported that 32% of hospital 
admissions were due to medications and drug interactions. 
Moczygemba et al. (2011), in a quasi-experimental non-equivalent control group 
study, assessed the impact of pharmacist-provided telephone MTM on medication, and 
health-related problems (MHRPs), medication adherence, and Part D costs.  The 
intervention group received the MTM service at the start of the study.  The assessment of 
MHRPs in the control group was done using retrospective electronic chart review.  MTM 
services consisted of a comprehensive medication therapy review, medication action plan 
and referrals.  Action plans included MHRP recommendations regarding (a) medication 
or dose changes, (b) drug safety and efficacy, (c) preventative care; (d) medication 
education (individually tailored), and (e) cost/formulary interchange.  All consultations 
were documented with follow-up to the patient’s primary care providers.  There were 4.8 
MHRPs identified in the intervention group at baseline, and 2.5 unresolved MHRPs at the 
6-month follow-up, a reduction of 48%. In the control group, 9.2 MHRPs were identified 
at baseline, with 7.9 unresolved MHRPs at follow-up, a reduction of 14%.  The 
intervention and control groups had similar adherence rates at baseline, 67%, and 68%, 
respectively.  At the 6 month, follow-up adherence rates remained unchanged at 67% and 
70%, respectively.  In the intervention group, the mean Part D drug cost decreased by 




from baseline to 6-month follow-up.  Moczygemba et al. (2011) noted that more than one 
consultation and a longer follow-up period might have been necessary to determine 
differences in medication adherence.  
The Moczygemba et al. (2011) study is important in demonstrating the success of 
a large private health plan using telephone and electronic medical records as an effective 
method to deliver MTM services.  Specific to this study, the focus was on MTM 
pharmacists engaging patients to optimize therapeutic outcomes while promoting safe 
and cost-effective medications.  Using electronic medical records MTM pharmacists are  
(a) able to evaluate patient medication adherence, and (b) assess whether medication use 
by the patient contributed to a MHRP or if medication had failed to achieve the desired 
outcome. 
Moore et al. (2013), using a PBM medical claims database, researched the 
relationship of MTM services on plan-paid health care costs, utilization of medical 
services, overall days’ supply of targeted medications, and changes in MPR for 5 
different chronic diseases (asthma, depression, diabetes, dyslipidemia, and hypertension).  
This large retrospective study used a quasi-experimental pre- and post intervention 
design.  Moore et al. studied the effect of MTM services on plan-paid health care costs, 
utilization of medical services, overall days of medication, and MPR.  The program 
intervention consisted of three consultations with clinical pharmacists over a time span of 
one year to discuss drug therapy.  The study found that the intervention group was 




only the conditions hypertension and dyslipidemia were statistically significant in 
increasing medication adherence. 
Although the problems of medical complexity specifically were not addressed by 
the Moore et al. (2013) study, the results correlated with a previous study by Choudhry et 
al. (2011).  Choudhry et al. concluded that as the number of medications an individual 
takes increases, the chance of medication nonadherence increases.  T2DM is a complex, 
chronic disease because of the coexistence of other comorbidities (hypertension, 
dyslipidemia, heart failure, and/or depression).  The treatment not only depends upon 
treating diabetes but the successful treatment of the comorbidities.  The significance to 
the current study is the importance of the pharmacist to recognize disease and medication 
complexity as it relates to the patient and medication adherence.  
Measuring Medication Complexity 
Polypharmacy is correlated with older adults and women; however, researchers 
have found that age and gender do not contribute to medication complexity (Corsonello 
et al., 2009; Mansur, Weiss, & Beloosesky, 2012).  George et al. (2004) asserted that 
when those who evaluate medications regimens for complexity should evaluate all the 
different variables of the regimen, just not the medication count.  Different variables 
include number of medications, dosage frequency and administration, and the medication 
dosage form (George et al., 2004). 
Until recently there was no industry standard to quantify medication complexity.  
To develop and validate the MRCI, information is used from medication charts, 




three sections; (a) information of dosage forms, (b) dosing frequency, and (c) additional 
directions.  The complexity index is the summation of weighted scores from the three 
sections.  The weightings are based upon the degree of difficulty.  In Section A, tablets 
and capsules are the most convenient compared to other dosage forms (liquids, gargles, 
sublingual sprays/ tabs, ointment, inhalation etc.).  Tablets and capsules are assigned a 
weight of 1; the other dosage forms are assigned a weight of 2 through 5.  In Section B, a 
tablet or capsule taken once a day is used as the baseline (Weighting 1).  Additional 
weighting of 0.5 was assigned for regimens that are administered at a fixed interval 
(twice a day versus every 12 hours).  Section C includes additional instructions per the 
manufacturer or the physician (e.g., after or before meals, or at a specified time during 
the day). George et al. (2004) tested the tool on a 134 different medication regimens from 
patients who had moderate to severe, chronic obstructive pulmonary disease.  This tool 
was shown to have an inter-rater and test-retest correlation reliability of ≥ 0.9 (p < 0.001) 
with respect to derived scores and expert panel rating medication regimen complexity 
(George et al., 2004). 
Libby et al. (2013) modified the MRCI to include a patient level MRCI subtype.  
Many disease states include other comorbidities.  Type 2 Diabetes Mellitus is often 
complicated with hypertension and hyperlipidemia.  The patient level MRCI subtype 
includes disease-specific medications, other prescribed medications, and over-the-counter 
(OTC) medications.  In their cross-sectional retrospective study, Libby et al. (a) 
compared patient-level MRCI scores across four chronic disease states (geriatric 




specific medication, other prescribed medications, and OTC medications in relation to the 
total MRCI score.  Geriatric depression had the highest total score, followed by HIV, 
diabetes and hypertension Libby et al. concluded that dosing frequency and other 
prescribed medications not related to the specific disease state heavily affected patient 
level scores.  In managing chronic disease states, it is vital to consider all the medications 
that an individual takes and not just disease specific.  
Conclusion 
The studies reviewed in this section suggest that MTM services can lead to a 
reduction in overall health care expenditures through increased medication optimization 
and adherence and reduction in medication errors.  Pharmacists today have an expanded 
role as clinical providers in assuming a professional responsibility for patient's 
medication therapy outcomes.  The literature shows that pharmacist involvement in 
patient care improves medication adherence and treatment outcomes.   
Proper treatment of chronic disease is dependent upon not only a health care 
system that recognizes the importance of the patient involvement in self-care; it also 
requires an extremely engaged patient (Remmers et al., 2009).  A fully engaged patient 
has confidence and skills to promote personal health and to continue this behavior for the 
long term (Remmers et al., 2009).  Studies show that supporting, teaching self-
management, and self-efficacy skills for T2DM patients improve health with lower costs 
of care (Dixon, Hibbard, & Tusler, 2009; Remmers et al., 2009).  Not all patients are on 
the same level of engagement, and as such, the pharmacists must tailor the patient 




Chapter 3 provides an overview of the quantitative research study designed to 
bridge the gaps in literature on patient engagement and telephonic pharmacist run MTM 
service.  Specifically, I will outline the techniques employed to explore the relationships 
between medication complexity, patient engagement, and medication adherence.  This 
includes the study design, proposed research questions, a description of the sampling 
frame, and power calculations based on available sample size.  I will also discuss the 





Chapter 3: Research Method 
Introduction 
The purpose of this retrospective quantitative study was to examine the 
relationship of a pharmacy benefit management (PBM) company’s medication therapy 
management (MTM) pharmacist telephonic consulting program. This program was 
designed to medication adherence and medication complexity for the selected PBM’s 
Medicare Part D recipients.  The study specifically analyzed the effectiveness of MTM 
pharmacist counseling as a means to improving medication adherence and compliance in 
an older adult population with type 2 Diabetes Mellitus (T2DM).  The treatment of 
T2DM requires lifestyle modifications, pharmacotherapy, and frequent blood glucose 
monitoring.  Achieving proper glycemic control requires education, motivation, and 
continuous support from health care professionals (ADA, 2013).  Medication therapy 
management pharmacists are able to take an active role in patient education, provide 
counseling in proper medication use, and address any barriers to adherence in the 
treatment of T2DM. 
This chapter details the research design and methods for this study, which 
analyzed a dataset consisting of PBM pharmacy claims data from a large, national 
employer prescription benefit plan in the United States.  Within the research design and 
rationale section, I review each of the research questions and provide a rationale for using 
multiple regression and correlation to determine the relationship of receiving MTM 
pharmacist counseling on medication adherence and on medication complexity.  The 




This includes the procedures for recruitment used by the PBM’s researchers from the 
original study (Moore et al., 2013).   
This discussion includes details on the predetermined sample size, my estimated 
power for the proposed analysis, and an explanation of the methods used in the power 
calculations.  Next, I review the instrumentation used in the original study, including 
methods to improve reliability and validity and the methods used in merging the data and 
creating the variables used in this study.  The data analysis section addresses the details 
of data review and cleaning, and describes the analytic methods in detail.  In the final two 
sections, I discuss the threats to internal and external validity, including steps I took to 
minimize them, ethical procedures taken to gain access to the data, and procedures used 
to protect the data and participants.  
Research Design and Rationale 
This study used two primary research questions.  
Research Question 1: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in 
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores 
after controlling for comorbidities? 
H01: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in 




HA1: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after 
controlling for age, gender, and comorbidities. 
Research Question 2: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in 
Medicare Part D beneficiaries having T2DM as measured by a change in MPR 
percentages after controlling for MRCI scores? 
H02: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in 
MPR percentages after controlling for MRCI scores. 
HA2: There is statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores.  
The first research question addressed if receiving MTM counseling has a 
relationship to medication complexity; the other, if receiving MTM counseling has a 
relationship to medication adherence.  The goal of both questions was to determine an 
associated relationship between independent and dependent variables.  To determine 
these relationships, participants were followed over time after an intervention has been 




The use of a cohort study design was appropriate for this study because there was 
preexisting evidence to suggest an association between an intervention and outcome and 
the interval between the intervention and development of the outcome was relatively 
short to minimize loss to follow-up, in accordance with the suggestions of Carlson and 
Morrison (2009) and Issel and Handler (2009).  Because cohort designs allow for data 
collection prior to the intervention, and due to the temporal nature of the design, cohort 
designs may be able to assess relationships (Carlson & Morrison, 2009; Issel & Handler, 
2009).  
Cohort studies are increasingly used in research as they combine elements of 
observation and experimental research methods, but have several distinct disadvantages.  
One is loss of participants to follow-up and the costs of maintaining contact during the 
evaluation follow-up (Carlson & Morrison, 2009; Issel & Handler, 2009).  Loss due to 
attrition may have adverse consequences for design validity and the statistical 
conclusions (Carlson & Morrison, 2009; Issel & Handler, 2009).  Another disadvantage 
is that there may be alternative explanations for the study results.  It is important, 
therefore, to consider confounding factors when evaluating study results (Carlson & 
Morrison, 2009; Issel & Handler, 2009). 
This research study used secondary data from health care claim records at a single 
PBM.  There are several advantages to using secondary archival data.  Doing so offers an 
economic approach and access to a larger data pool, and it may establish observations 
that may not have been present at the time of the original data collection (McKenzie, 




researchers with increased opportunities to develop new knowledge (McKenzie, Neiger, 
& Thackeray, 2009).  Another advantage of using secondary data is that such data are 
more readily available than primary data.  In contrast, a major disadvantage is that there 
is less control over data collection and data entry and one cannot determine firsthand the 
reliability and validity of the data (Issel & Handler, 2009).  Another disadvantage is that 
secondary data may be several years old (Issel & Handler, 2009). 
Methodology 
Population 
This secondary data analysis reused data from a study conducted by a PBM 
company in 2013 (Moore et al., 2013).  Moore et al. (2013) used data from 4,500 high-
risk members of a large employer group to examine the effectiveness of MTM on therapy 
adherence and clinical outcomes.  All member participants in  Moore et al.’s study had a 
diagnosis of asthma, depression, T2DM, hypertension, and/or hyperlipidemia. The 
current study used a subset of Moore et al.’s (2013) population, consisting of high-risk 
plan members 65 years and older who were recorded as having T2DM.  The PBM study 
database used by Moore et al. provided eligibility information, pharmacy claims, and 
medical claims for the T2DM subset (n = 1,157), who were identified using the ICD-9 
code of 250.x.  
Power analysis.  Statistical power depends on three classes of parameters: (a) the 
significance level (α), (b) the size of the sample used for the intervention, and (c) the 
effect size (f 2), the expected differences in the means between the control and 




Conventional set values for these three factors are usually set as α = 0.05, power (1-β) = 
0.80, and medium effect size (f 2) = 0.15.  The power (1-β) of a study, typically presented 
as high, medium, or low, denotes the beta error probability of falsely retaining an 
incorrect null hypothesis.  
I conducted a post hoc power analysis because this was a secondary analysis of an 
already published study (Cohen, 1988; Faul, Erdfelder, Land, & Buchner, 2007).  Post 
hoc power analysis was obtained using G*Power 3.1.2 (Faul et al., 2007).  In a post hoc 
analysis, power is computed as a function of alpha, the population effect size, and the 
sample size used in the study.  For this post hoc analysis, I used a small effect size (f2 = 
0.02, alpha = 0.05), and a sample size of 1,157.  The post hoc analysis using multiple 
regression revealed that a sample size of 1,157 with two predictors and four predictors 







Figure 1. A graph showing the post hoc analysis distribution. 
 
Sampling and Sampling Procedures 
The target population for the original study was comprised of high-risk plan 
members, from a large nationally diverse managed care health (Moore et al., 2013).  Plan 
members were considered high-risk if they  
• were 18 years of age or older;  
• were heavy prescription users (14 or more claims in a 3-month period); 
and 
• had a pharmacy profile that showed the absence of a recommended 
treatment therapy or the presence of a conflicting treatment therapy in the 
treatment of conditions such as asthma, T2DM, hypertension, 




Pharmacy benefit management MTM pharmacists identified a total 13,092 high-
risk plan members between October 1, 2007, and November 12, 2008 (Moore et al., 
2013).  Plan members were excluded if they had dual coverage of Medicare and 
Medicaid or lacked medical plan payments (n = 8,723).  After completing three pharmacy 
consultations with clinical pharmacists, 2,250 plan members enrolled in the program and 
6,463 plan members declined.  Plan members that declined during this period became 
part of a control group (n = 2,250).  The original study consisted of 4,500 plan members.  
Propensity scoring was used to match the control group to the intervention group.  The 
T2DM subgroup consisted of 1,157 plan members, 546 were in the intervention group, 
and 611 were in the control group.   
Procedures for Data Collection 
The collection of primary data using the high-risk plan members was performed 
prior to this study (Moore et al., 2013), and PBM pharmacy personnel handled all data 
entry.  The PBMs pharmacy systems were responsible for quality assurance including 
checking data entry for errors.  The original data are stored and saved on a directory in 
this PBM data environment.  The data was not archived but saved as a data set.    
I obtained the diabetes data set from this PBM after approval of my proposal by 
Walden University Institutional Review Board (IRB).  All data requested from this PBM 
was required go through the mandatory Confidential Information Access Request (CIAR) 
process, the formal proposal in writing outlining the need for proprietary study data.  
After approval of my CIAR, I gained access to the data files from J. Moore, a member of 




al., 2013).  Prior to releasing the electronic files to me, Moore de-identified the data, 
removing all personal identifying markers (i.e., names, addresses, Social Security 
numbers, and plan member identification numbers).  The CIAR document approval is 
located Appendix B.   
Instrumentation and Operationalization of Constructs 
Treatment complexity.  All patients in the diabetes cohort were assigned a 
complexity score based upon an algorithm developed by George et al. (2004).  The 
Medication Regimen Complexity Index (MRCI) is an instrument composed of 65-items 
used to quantify complexity of medication regimens and has been used in adherence 
studies (Libby et al., 2013; McDonald et al., 2013; Pollack et al., 2010).  The MRCI was 
found to be valid with an inter-rater and test-retest reliability of ≥ 0.9 (George et al., 
2004) and valid tool for quantifying the complexity of medication regimens (Libby et al., 
2013; McDonald et al., 2013; Pollack et al., 2010).  The instrument consists of three 
sections: (a) route of drug administration, (b) dosing frequency, and (c) additional 
directions.  Additional directions are recommendations by the manufacturer product 
insert (Facts & Comparisons eAnswers, 2013) or physician, which a patient may need to 
follow in adhering to a prescribed regimen (e.g., at a specific time).  The sum of the three 
sections contributes to the complexity index.  This study used only those items in the 
MRCI that were applicable to oral and topical prescription medications.  The MRCI was 
calculated from the drug database at baseline and then after the intervention.  The 




MTM pharmacists in identifying patients who may have been at a higher risk medication 
nonadherence. 
Calculating MRCI score.  The original index includes the summation of 
weighted components of (a) dosage form, (b) dosing frequency, and (c) additional 
administration instructions (see Appendix A).  For a patient taking medications, the 
minimum MRCI index score would be 1.5.  This score represents a single tablet or 
capsule taken once daily as needed; the number increases with the number of 
medications.  
Component A: Dosage form/route.  Component A incorporates a weighting 
scheme for dosage forms (tablet/capsule vs. spray vs. drop vs. ampoule), and route of 
administration.  Nasal sprays, oral or ophthalmic drops, and subcutaneous ampoules are 
considered more complex than tablets or capsules and are given a heavier weight.  The 
MRCI developers provided weights for 32 different combinations.  For this study, I only 
used items in the MRCI that were applicable to oral medications and topical patches 
pertinent to diabetes and associated comorbidities.  Representative combinations are 
presented in Table 1 (alignment of PBM data to MRCI components).  To tabulate Section 
A, a given form/route combination is counted only once within a regimen.  For example 
if a patient takes two capsules and two tablets, the subset score for Section A is 1.  
However, if a patient takes two tablets and uses a nasal spray, then the patients' subset 
score for A is 3.  
Component B: Dosing frequency.  George et al. (2004) included 23 weights 




taken or used every2 hrs.  For this study, only dosing frequencies applicable to oral 
maintenance medications was used (see Table 1).  Dosing frequency is tabulated to 
account for all medications.  For example if the patient is taking two tablets and two 
capsules and all four medications are taken once a day, the Component B subset would be 
scored as 4.  If a patient were taking two tablets each once a day and uses a nasal spray 
on alternate days, the Component B subset score would be 4. 
While it may be helpful to identify a given medication and possible dosing 
frequency, this information does not provide specific dosing information for a specific 
individual.  Frequency is not in automatic property linked with a manufacturer's 
identification number.  For this study, drug dosing was calculated per the manufacturer’s 
suggested dosing and days’ supply of medication.  
Component C: Additional directions.  George et al. (2004) provided for 10 
additional directions a patient may need to follow for a patient to be fully medication 
adherent (George et al., 2004).  Special instructions were obtained from the patient 
message code that was linked to the drug identification number.  Table 1 Component C 
represents examples and their assigned weights.  A weight is given per each instruction 
per medication.  For example, if a patient needs to take two capsules needed before 
breakfast and two tablets at bedtime, then Component C subset score is 4.  The MRCI 
score for this patient would be the sum of section A (1) + B (4) + C (4) = 9.  The higher 
the MRCI score of the medication regimen, the more complex the regimen becomes 






Table 1  
 
Alignment of PBM Data to MRCI Components  
 
MRCI component A: 
form/route- weight 
MRCI component B:  
dosing frequency- weight 
MRCI component C:  












Break or Crush tablet  
or 
Do not break or crush 
 
1 
Liquids oral 2 Twice a day 2 Multiple units at one 
time 
1 
Sublingual oral 2 Three times a day 3 Take at specific times 1 
   Four times a day 4 Take in relation to 
food 
1 
   On alternate days or less 
frequently 
2 Variable dose 1 
     Tapering or increasing 
the dose. 
2 
     Alternating the dose 2 
     Take as directed 2 
Note.  Adapted from George, J., Phun, Y., Bailey, M. J., Kong, D., & Stewart, K.(2004). Development 
and validation of the medication regimen complexity index. The Annals of Pharmacotherapy, 38(24)1369-
1376. doi:10.1345/aph.1D479 
.   
 
Treatment adherence.  The MPR, a measure of adherence, was calculated for 
each patient in the study for each oral medication that the patient used.  Medication 
possession ratios were calculated from claims data as the sum of days during the year 
when the patient had the medication divided by the number of days in the year.  The 
MPRs for each oral medication were then weighted by the percentage of time.  An 
average composite score was computed for each patient.  The value of the MPR ranges 




(80%) (Choudhry et al., 2009; Osterberg & Blaschke, 2005; Zhang et al., 2010).  
Medication possession ratios for this study were calculated at baseline and then after the 
intervention. 
Study Variables and Covariates 
Dependent Variable 
The dependent variables were medication adherence and medication complexity.  
The medication possession ratio measures medication adherence, and changes in this 
ratio indicate whether individuals are more or less adherent to their medication regimens. 
Increased adherence with medication regimens lessens adverse events.  The Medication 
Regimen Complexity Index (MRCI) measures medication complexity.  Medication 
Regimen Complexity Index is a composite number that represents the complexity of an 
individual's medication regimen.  Reducing the MRCI score represents a less complex 
medication regimen.  Simplifying medication regimens increases medication adherence.  
Both the MRCI score and MPR ratios are measured before the intervention and then after 
the intervention.  Medication adherence and medication complexity, their source, 
potential responses, and level of measurement are presented in Table 2.  
Independent Variable 
The MTM program is the intervention and the independent variable for this 
research.  Medication therapy management programs essentially are to resolve and 
prevent drug therapy problems and increase medication adherence.  The primary focus 
was the changes in MRCI scores and MPR ratios.  Medication therapy management 





The covariate in this study included age, gender, and comorbidities.  Studies 
(Doggrell, 2010; Lehane & McCarthy, 2006) have shown that age itself not necessarily 
influences medication nonadherence; however, poor disease management may represent a 
greater risk for older adults due to multiple co-morbidities and multiple medication use, 
leading to medication complexity.  Polypharmacy correlates with increased ADEs, 
medication nonadherence, health-care costs, hospitalization, and mortality (Budnitz et al., 








Response Source of data 
Dependent MPR± Continuous percentage Calculated† 
Dependent MRCI* Continuous  Range from 3-60 Calculated† 
Independent MTM** counseling 
program 
Nominal Yes/No PBM claims 
database 
Covariates Age Continuous Age in years  PBM claims 
database 
Covariates Gender Nominal Male/Female PBM claims 
database 
† See discussion of calculations in instrumentation and operationalization 
± Medication Possession Ratio, * Medication Regimen Complexity Index, **Medication Therapy 
Management 
 
Data Analysis Plan 
This was a quantitative secondary analysis of a cohort study on MTM pharmacist 
counseling program from a large PBM company on medication adherence and clinical 
outcomes on high-risk individuals (Moore et al., 2013).  The primary study identified the 




dependents.  Medication therapy management (MTM) pharmacists from the PBM 
stratified the target population into two groups, intervention, and control.   
Descriptive statistics using SPSS v.21 described the patient characteristics.  Each 
patient's age, number of medical conditions, number of medications and medication 
complexity were described as the means.  Medication adherence was labeled as a 
percentage.  I used a two-sided tail in all analysis and a p-value of less than or equal to 
0.05 was considered statistically significant. 
Analysis Plan for Research Question 1  
 I used correlation and multiple regression analysis to see if there was an 
association between receiving MTM pharmacist counseling (independent variable) and 
medication complexity (dependent variable) and to measure the strength of the 
relationships between both variables while controlling for age, gender, and comorbidities.  
The hypothesis was expressed as a p-value, the correlation coefficient r2 described the 
strength of the relationship, and the regression line illustrated the relationship of the 
variables.  The coefficient correlation can fall anywhere between -1 to 1.  The closer the 
value of r2 is to 1, the stronger the linear correlation.  A value of 0 denotes little or no 
linear correlation.  To test for the hypothesis, tstat = r/SEr, where SEr =  √ 1- r2/n - 2 
degrees of freedom.  Squaring r derives a statistic called the coefficient of determination 
(r2), which quantifies the proportion of the variance in the dependent variable 
(medication complexity) explained by the independent variable (MTM pharmacist 
counseling).  The t-stat is converted to a p-value.  The hypothesis would rejected if p < 




Analysis Plan for Research Question 2   
I used correlation and multiple regression analysis to see if there was an 
association between receiving MTM pharmacist counseling (independent variable) and 
medication adherence (dependent variable) and to measure the strength of the 
relationships between the both variables while controlling for MRCI scores.  The 
hypothesis was expressed as a p-value, the correlation coefficient r2 described the 
strength of the relationship, and the regression line illustrates the relationship of the 
variables.  The coefficient correlation can fall anywhere between -1 to 1.  The closer the 
value of r is to 1, the stronger the linear correlation.  A value of 0 denotes little or no 
linear correlation.  To test for the hypothesis, tstat = r/SEr, where SEr= √ 1- r2/n - 2 
degrees of freedom.  Squaring r derives a statistic called the coefficient of determination 
(r2), which quantifies the proportion of the variance in the dependent variable 
(medication adherence) explained by the independent variable (MTM pharmacist 
counseling).  The t-stat is converted to a p-value.  The hypothesis would be rejected if p < 
0.05.   
Correlation and multiple regression are appropriate tests when there are 
continuous and a nominal variables, and to check if two variables are associated, without 
necessarily inferring a cause-and-effect relationship (McDonald, 2009).  Assumptions 
using correlation and multiple regression are that there is normal distribution, equal 
variance (homoscedasticity), data will fit a straight line, and data points are independent 




homoscedasticity and a scatter plot to test for linearity.  All analysis was done using 
SPSS v.21. 
Threats to Validity 
Internal Validity 
The internal validity is the degree to which the study design accurately reflects 
whether the change that was measured can be attributed to the program.  An important 
question of internal validity is whether the observed changes can be attributed to the 
intervention and not to other possible causes or alternative explanations (Trochim & 
Donnelly, 2008).  A randomized experiment is the strongest in of designs in establishing 
relationships.  Using a randomized control experiment was not feasible for this PBM.  
Quasi-experimental design studies do not possess the strength of randomized experiments 
for establishing evidence of program effect; however, quasi-experiments can provide 
moderate strength of program effect (Austin, 2011).  Because of the lack of random 
assignment, extraneous confounding variables may negatively influence program effect.  
In quasi-experimental design studies, participant characteristics (e.g., age, gender, SES, 
industry, etc.) can influence selection bias (Austin, 2011).  Propensity scoring allows for 
the mimicking of some of the characteristics (reduction or elimination of confounding 
effects) of a randomized controlled trial so that the effect of treatment on outcomes can 
be estimated directly between intervention and control groups (Austin, 2011).   
In the original study by Moore et al. (2013), authors address the potential self-
selected control group bias; Moore et al. used propensity score matching to match the 




on plan-paid health care costs, utilization of medical services, overall day's supply of 
targeted medications, and MPRs.  The following characteristics were used: age, gender, 
baseline day's supply of medications, baseline plan-paid pharmacy costs and medical 
costs, physician and inpatient visits, and number of pharmacy-derived chronic disease 
states.  Individuals for this study were not matched on specific disease states, such as 
depression or diabetes (Moore et al., 2013).  
External Validity 
Medication therapy management was created to be different from all other 
counseling program, as fully explained in Chapter 2.  More specific, to be eligible, 
recipients must have multiple chronic diseases, must be on prescription medication 
covered under Medicare Part D drugs, and must be age 65 years and older.  External 
validity is the extent to which the program can be expected to produce similar effects in 
other populations (McKenzie, Neiger, & Thackeray, 2009).  The more tailored a program 
is to a particular population, the less likely the program can be generalized to other 
population and the greater the external validity.  The present study focused on the 
Medicare eligible recipients who have T2DM only.  To improve the validity of the study, 
the sample included participants from across the United Sates who were insured with this 
large employer prescription benefit plan. 
Ethical Procedure Information  
This study did not involve experimentation on human participants, and it was 
limited to retrospective review of secondary data collected during a previous study done 




and removed names, Social Security numbers, insurance identification numbers, and 
other personal information from the electronic data file.  With the approval of Walden’s 
IRB, permission to access information, data review, and analysis, a formal Confidential 
Information Access Request (CIAR) was filed with the chief privacy officer of the PBM.  
All electronic information remains the property of the PBM.  No personal information 
was used in describing the study and its results.   
Summary 
In this study, I used a quantitative approach of a secondary data source to examine 
the role of MTM pharmacists on medication complexity and adherence.  I aimed to 
identify the relationship of receiving MTM pharmacist counseling on medication 
adherence and complexity in the older adult population.  The study follow-up cohort was 
limited to participants who had been identified as high-risk members 65 years and older, 
had T2DM, and had belonged to a large employer group. 
Chapter 3 provided the detailed methodology for this quantitative secondary data 
analysis.  Using a cohort design, I used multiple regression and correlation to test the 
hypotheses that there may be a relationship in receiving MTM pharmacist counseling on 
medication adherence and complexity in older adults.  Chapter 4 reports the summary of 
the results of this quantitative secondary data analysis that either supports or does not 






Chapter 4: Results 
Introduction 
The purpose of this quantitative study was to examine the relationship of a 
pharmacy benefit management (PBM) company’s Medication Therapy Management 
(MTM) telephonic pharmacist-consulting program to medication adherence and 
medication complexity. It specifically examined this relationship with a group of 
Medicare Part D recipients serviced by a single PBM, using a secondary data set from a 
previously published study.  As described in Chapter 3, multiple regression was used as 
the primary statistical analysis. 
The results of my study revealed that there was not a statistically significant 
relationship between receiving MTM pharmacist support and medication complexity, and 
MTM pharmacist support and medication adherence.  However, small in magnitude, 
there was a statistically significant association between comorbidities and medication 
complexity.    
This chapter describes the analysis and results conducted to address the study’s 
two research questions.  The research questions and associated null hypothesis for this 
study were: 
Research Question 1: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in 
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores 




H01: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in 
MRCI scores after controlling for age, gender, and comorbidities. 
HA1: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after 
controlling for age, gender, and comorbidities. 
Research Question 2: Is there an association between receiving MTM pharmacist 
telephonic support and medication adherence in Medicare Part D beneficiaries having 
T2DM as measured by a change in MPR percentages after controlling for MRCI scores? 
H02: There is not a statistically significant association receiving medication 
therapy management pharmacist telephonic support and medication adherence in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores. 
HA2: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores.  
Data Collection 
This study used secondary archival data exclusively.  After receiving approval 




Confidential Information Access Request (CIAR) process, I acquired four datasets in 
Microsoft Excel format: PCare, GPI drug data, Pre-intervention GPI, and Post-
intervention GPI.  The four Excel datasets were downloaded by me from the PBM’s 
secure transport system, converted to an SPSS format, and stored on an external hard 
drive.   
The datasets contained the following information:   
1. The PCare dataset contained the demographic information on the T2DM 
study population and the independent variable MPR.    
2. The GPI Drug dataset contained the medications that the T2DM 
population were receiving or had received during the study period.  Each 
medication record included the medication dosage form (tablet, ointment, 
creams, patches, intravenous and/or subcutaneous route), strength of each 
medication and any pertinent special instructions by the manufacturer.  
Not all medications have special instructions from manufacturers (see 
Appendix A).   
3. The Preintervention GPI dataset contained the random ID numbers of the 
population, associated medications for each random ID, and days’ supply 
of each medication prior to the intervention.   
4. The Postintervention GPI dataset contained the same information as the 






Creation of New Variables, Total MRCI and Total Medication Count  
The GPI Drug data set required the creation of two additional independent 
variables., which were labeled TMRCI and TMeds.  These variables were created to 
explain medication complexity.  In creating the TMRCI variable, as one of two of 
additional variables to the GPI Drug dataset, I deleted all the records that represented 
medications that were in liquid form, intravenous and subcutaneous route, creams, or 
ointments.  From this modified version, I created a new variable TMRCI.  In order to do 
this, I first created individual MRCI scores for each drug (Appendix A).  Each MRCI 
score is the sum of three components (Component A + Component B + Component C).   
• Component A (drug dosage form, tablet, capsule or patch) was weighted 
either as 1 or 2.  
• Component B (drug dosing frequency) was weighted from 0.5 to 4 
depending upon the manufacturer’s recommended dosing.  
• Component C (special instructions) was weighted from 0 to 3 depending 
upon the drug manufacturer’s warnings and precautions.  Some 
medications had more than one precaution leading to a higher score.   
This modified data set was coded as Drug Data with MRCI.  The individual 
MRCI scores were added to the pre- and postintervention GPI data set and the two new 
databases were coded as Preintervention MRCI and as Postintervention MRCI.  From 
both of these datasets, I then computed a total MRCI (TMRCI) score and total medication 
count for each random ID record.  The variables TMRCI and total medication count 




each random ID record in the Preintervention MRCI and Postintervention MRCI datasets.  
These two new variables were added to the Pcare dataset.  
Results 
Descriptive Statistics of Participants 
The study population consisted of the T2DM subset of a group of high-risk plan 
members aged 60 years and older and enrolled at a single PBM Company that provided 
data. All source data consisted of a secondary dataset from a previous study conducted by 
this PBM Company in 2013 (Moore et al., 2013).  The extracted dataset used in the 
current study consisted of data that represented 1,158 participants.  These data sets were 
first scrubbed for missing responses and extreme scores (outliers) that might affect the 
results of the statistical analyses.  Three records were removed due to missing data 
(diabetic MPR change scores).  In addition to identify outliers, the raw scores were 
converted to z scores where 0 was the mean and the standard deviation was 1.  Scores that 
were higher or lower than 99% of the other scores (z = 3.29+/-) were considered extreme, 
resulting in the removal of the associated records.  Six scores met this criterion.  After 
screening, complete and nonoutlying data were available on 1,148 records (Intervention n 
= 543, Control n = 605).   
For the T2DM study population, the ages ranged from a minimum of 60 years to a 
maximum of 97 years, with a mean age of 75 years and a median of 76 years.  There 
were 301(49.8%) men and 304 (50.2%) women in the control group, and 258 (47.5 %) 
males and 285(52.5%) in the intervention group, which equaled 1,148 participants (Table 




statistical differences between gender with (p = 0.809).  There was a statistical difference 
between the groups in comorbidity count of two or less (p = 0.028).  The total number of 
medications per participant at baseline, ranged from 1–20, with a mean and median of 
eight.  The differences between the groups were not statistically different (p = 0.33).  
Gender differences were not statistically different (p = 0.556).  
Table 3 
 
Demographic Characteristics of Study Participants 
Study Group 
Gender 
Total Males  Females  
Control 
% within Study Group 
n = 301 
49.8 % 
n = 304 
50.2% 
n = 605 
100% 
Intervention 
% within Study Group 
n = 258 
47.5% 
n = 285 
52.5% 
n = 543 
100% 
Total 
% within Study Group  
n = 589 
48.7% 
n = 559 
51.3% 















Gender and Comorbidity Count Study Group Cross-tabulation 
Comorbidities 
Gender Study Group  
Male  Female Control Intervention Total 
2 or less Count 

















3 or more Count 
% within Comorbidities 

















% within Comorbidities 


















Research Question 1: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in 
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores 
after controlling for age, gender, and comorbidities? 
H01: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in 




HA1: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after 
controlling for age, gender, and comorbidities. 
The means and standard deviations for the MRCI raw scores are shown in Table 
5.  As observed, there was no statistical difference between the pre and post raw scores 
for the two groups.  Further, for each participant, a change score was obtained which was 
the difference between pre- and postintervention.  This difference could show no change 
in complexity, a decrease, or an increase in complexity.  Here again, the two groups were 
not statistically different. 
Table 5 
Descriptive Statistics for MRCI Raw Scores and Percent’s for Direction of Change 
Scores for the Intervention Group (n = 543) and the Control Group (n = 605) 
 
  MRCI Complexity 
Group 





% M SD M SD 
Intervention 23.03 8.42 22.84 7.98 16.2 41.5 42.3 
Control 22.84 9.56 22.56 9.51 12.3 43.3 44.4 
 
As described in Chapter 3, multiple regression was employed to examine the 
association between the MTM program and medication complexity after controlling for 
age, gender, and comorbidities.  The descriptive statistics for these variables are provided 
in Table 6.  For purposes of the regression analysis, the MRCI change score was 




independent variables and considered as covariates in the regression analysis.  The 
differences between the mean change scores for the two groups as well as the covariates 
for the two groups were small and similar to Table 5.  The change scores ranged from -24 
to 36.  Minus or negative scores reflected greater complexity on the post MRCI while 
positive change reflected less complexity.  As such, the means for MRCI change indicate 
that, on average, both groups showed slightly less complexity on the MRCI post-
intervention while their standard deviations indicate that there was wide variability within 
each group.  Observation of the covariates also indicates that the groups were quite 
similar. 
Table 6  
 
Descriptive Statistics for MRCI Change and Covariates for the Intervention Group (n = 
543) and Control Group (n = 605) 
 
 MRCI change Covariates 
Group M SD 
Comorbidities Age Male Female 
M SD M SD n % n % 
Intervention 0.28 6.94 3.37 0.74 74.6 8.14 258 47.5 285 52.5 
Control 0.20 6.36 3.25 0.82 75.7 8.08 301 49.8 304 50.2 
 
Table 7 further describes the variables through their bivariate correlations with 
each other.  Correlation and regression require the measures on each participant to be 
numerical.  To meet this requirement group membership was coded as 0 (control group) 




Row 1 of the matrix is of most interest and informative.  It shows that the 
dependent variable (MRCI Change) had near zero correlation with the primary 
independent variable of group (r = 0.01).  Reading further across the row indicates zero 
and near zero correlations between MRCI Change for age and gender.  While the 
correlation with comorbidities was statistically significant it was small in magnitude (r = 
0.10, p < 0.05).  The correlations thus support the previous descriptive statistics in Tables 
5 and 6, which suggest that the association between group membership and MRCI 
Change would be small. 
Table 7 
 
Intercorrelations between MRCI Change, Group, and Covariates 
 
Variable MRCI Change Group Age Gender Comorbidities 
MRCI Change __ 0.01 0.00 -0.02 0.10** 
Group  __ -0.07** 0.02 0.08** 
Covariates 
  
   
Age __ -0.01 -0.06* 
Gender  __ 0.10** 
Comorbidities   __ 
*p < 0.05, **p < 0.01. 
 
Based on the descriptive statistics and correlations provided above, the 
expectation was that the regression analysis would not reveal additional information 
about the association between group membership and MRCI Change.  However, it was 
felt that it would be useful to include it as part of this analysis.  Hierarchical multiple 
regression was the procedure employed.  In this approach, the variables were entered in 




variables that are considered as covariates.  As part of the procedure, the data were first 
examined for the assumptions underlying regression and no violations were found.  
Assumptions using correlation and linear regression are that there is normal distribution, 
equal variance (homoscedasticity), data will fit a straight line, and data points are 
independent of each other (McDonald, 2009).  The 0.05 level of probability was used as 
the criterion for statistical significance. 
Provided in the table are the standardized beta weights (β), the t-ratios, statistical 
probabilities (p), the multiple correlation (R).  Whereas Table 7 provides the bivariate 
correlation (r) between each set of two variables, multiple correlation is the correlation 
when variables are combined together.  Of interest in hierarchical regression is the 
change in the multiple correlation (R) as the variables are combined as the analysis 
proceeds from step-to-step.  
For these data, there were four steps.  The first step was the primary independent 
variable (group) and its association with the dependent variable, medication complexity 
(MRCI Change).  Because it is the first step and just two variables (MRCI Change and 
Group), the multiple correlation (R = 0.01) is the same as the bivariate correlation in 
Table 7 (r = 0.01).  Age was entered as Step 2 and contributed no change to R.  This 
coincides with Table 7, which shows that there was no correlation between age and 
MRCI Change (r = 0.00).  When gender is added in Step 3, the multiple correlation 
increased slightly (R = 0.02) since it is the combined relationship between MRCI, group, 
age, and gender.  Comorbidities were entered as the final step and the multiple correlation 




R.  To be statistically significant p had to be 0.05 or less.  The p value for t = 3.44 was 
0.01 thus showing statistically significance beyond the 0.05 criterion.  
The standardized beta weight (β) is useful in that from a prediction perspective 
the weights may be compared directly.  Observation of the weights indicates that 
comorbidities would contribute nearly 10 times more weight in predicting medication 
complexity (MRCI Change) than any of the other variables.   
In summary, for research question 1, no support was found for an association 
between MTM telephonic support and medication complexity as measured by a change in 
MRCI scores.  Thus, the null hypothesis (H01) was not rejected.  The only association 
found was between comorbidities and medication complexity as measured by change in 








Step and Variable      β   t   p   R   
________________________________________________________________________ 
  Step 1 
   Group      0.01  0 .20  0.84  0.01  
Covariates 
  Step 2 
   Age       0.00   0.11  0.92  0.00  
 Step 3 
   Gender    -0.02  -0.50  0.62  0.02  
 Step 4 





Research Question 2: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in 
Medicare Part D beneficiaries having T2DM as measured by a change in MPR 
percentages after controlling for MRCI scores? 
H02: There is not a statistically significant association between receiving 
medication therapy management pharmacist telephonic support and medication 
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in 
MPR percentages after controlling for MRCI scores. 
HA2: There is a statistically significant association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in the 
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores.  
The means and standard deviations for the variables used for this research 
question are shown in Table 9.  The pre and postintervention means and standard 
deviations indicate small differences between the two groups for MPR.  The Percent 
Change values indicate that there was some difference between the means with much 
greater variation within the intervention group as shown by the standard deviations.  The 
MRCI means and standard deviations are the same as those in the previous research 












Descriptive Statistics for Pre and Post-MPR, MPR Percent Chang, and the MRCI 
Covariate for the Intervention Group (n = 543) and Control Group (n = 605) 
_______________________________________________________________________ 
 
               Pre-MPR  Post-MPR    % Change            Pre-MRCI 
 
Group   M SD  M SD M  SD    M  SD 
________________________________________________________________________ 
Intervention  .77 * .25 .78* .27 .64 8.95  23.03 8.42 
Control  .74* .25 .73* .29 .22 1.93  22.84 9.56 
_______________________________________________________________________ 
* Multiply ratio by 100 to equal percentage.  80% is considered adherent. 
 
The correlations observed in Table 10 indicate small relationships between the 
three variables with the correlation between the medication adherence (MPR percent 
change) and group being near zero (r = 0.03).  Although the correlation between 
medication complexity (Pre-MRCI) and medication adherence (MPR Percent Change) is 




Intercorrelations between MPR Percent Change, Group, and Covariate 
_____________________________________________________________________ 
 
Variable   MPR % Change  Group  Pre-MRCI 
  
____________________________________________________________________ 
MPR Percent Change   __     0.03       0.05* 
 
Group          __       0.01 
 
Covariate 
   Pre-MRCI              __ 
______________________________________________________________________ 





Hierarchical regression was also used to examine research question 2.  The results 
shown in Table 11 indicate no statistical support for an association between the MTM 
pharmacist telephonic support program and medication adherence as represented by the 
percentage change scores. 
Table 11 




Step and Variable     β     t    p  R  
________________________________________________________________________ 
  Step 1 
   Group    0.03   1.11  0.27  0.03 
  
Covariates 




The study examined an MTM pharmacist telephonic consulting program and its 
relationship to medication complexity and adherence to medications.  Regression 
analyses on post program complexity and adherence change scores showed no correlation 
between MTM telephonic pharmacist support and the reduction in complexity or an 
increase in adherence.  However, regression analysis did show that comorbidities were 
influential in predicting medication complexity (MRCI Change) than any of the other 
variables.   
In Chapter 5, I discuss the results presented in this chapter and interpret them in 




population, and MTM pharmacists and propose further research to validate these results 
and explore using MRCI score as a tool in greater depth as well recommend PBM MTM 
interventions to reduce medication complexity and increase medication adherence in the 






















Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this quantitative study was to examine the relationship of a 
pharmacy benefit management (PBM) company’s Medication Therapy Management 
(MTM) telephonic pharmacist-consulting program to medication adherence and 
medication complexity. It specifically examined this relationship with a group of 
Medicare Part D recipients serviced by a single PBM, using a secondary data set from a 
previously published study.  The study controlled for age, gender, and comorbidities, and 
was designed to answer two primary research questions: 
1) Is there an association between receiving medication therapy management 
pharmacist telephonic support and medication complexity in Medicare -D 
beneficiaries having T2DM as measured by a change in MRCI scores after 
controlling for age, gender, and comorbidities? 
2) Is there an association between receiving medication therapy management 
pharmacist telephonic support and medication adherence in Medicare -D 
beneficiaries having T2DM as measured by a change in MPR percentages 
after controlling for MRCI scores? 
This retrospective study used quantitative archival data from a PBM located in the 
Midwest region of the United States.  Regression analysis tested whether there were 
changes in postprogram complexity and adherence by the MTM’s pharmacist telephonic 
support; the overall findings showed no statistical correlation between MTM telephonic 




However, regression analysis did show that after controlling for the covariates 
comorbidities, age, and gender, comorbidities significantly (p=0.01) predicted medication 
regimen complexity than age or gender.  These findings suggested that in complex 
disease states such as Type 2 Diabetes Mellitus (T2DM), there is no statistical correlation 
between MTM pharmacist telephonic support and medication adherence. 
Interpretation of the Findings 
Type 2 Diabetes Mellitus is often considered a complex disease and is the 
seventh-leading cause of death and morbidity in the United States (ADA, 2013; Qaseem 
et al., 2012).  Type 2 Diabetes Mellitus is the most common form of diabetes and its 
prevalence increases with age; at the time of the study, nearly 25% of the United States 
population older than 65 years had T2DM (Qaseem et al., 2012).  If left untreated or 
poorly treated, the disease leads to microvascular (retinopathy, nephropathy, and 
neuropathy), and/or macrovascular (coronary artery disease, heart failure, 
cerebrovascular and peripheral vascular disease) complications (ADA, 2013; Qaseem et 
al., 2012).   
  Adherence is a key link in obtaining positive outcomes for medical care.  
Medication Possession Ratio percentages (ratios) in this study were used to represent 
medication adherence.  This study used stages of change (SOC) theory as its theoretical 
foundation, which describes the stages of readiness, the decisional balances, and self-
efficacy used by individuals in making a behavior change. These changes usually occur 
in stages, and are not always linear (Prochaska & DiClemente, 1983).  Pharmacists are 




maintain adherence to pharmacological treatment for improving the prognosis of T2DM 
(Rodriguez de Bittner & Zaghab, 2011; Viswanathan, 2012).   
The study results showed that there was neither increase nor statistical decrease in 
medication adherence in the T2DM population.  The treatment guidelines for treating 
T2DM are annually updated to promote better management of this population, and as 
such, treatment may becomes more complicated.  T2DM treatment not only includes the 
medication for the disease itself, but also includes medications for preventative use for 
downstream complications and medications for the associated comorbidities that may be 
present (ADA, 2013).  Many consultations with the patients and pharmacists end with 
new medications added to patients’ already complex regimens due to the standard 
treatment guidelines for T2DM.  For successful MTM consultations, pharmacists need to 
use combinations of skills that will assist patients with taking their medication and any 
new life-style changes into a patient’s life.  Adherence to prescribed medication is crucial 
to therapeutic success. 
MTM Pharmacist Telephonic Support and Medication Complexity 
Research Question 1: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication complexity in 
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores 
after controlling for age, gender, and comorbidities? 
Quantifying regimen complexity is a concept that was introduced in 2004 by 
George et al. (2004).  Medication complexity is more than the amount of tablets that a 




usage instructions and varies from one medication to another (George et al., 2004, Libby 
et al., 2013). For example, Choudhry et al. (2011) showed that patients’ making multiple 
pharmacy trips is a significant factor in therapeutic complexity.  Medication complexity 
is strongly correlated with medication nonadherence (Choudhry et al., 2011; Corsonello 
et al., 2009; Libbey et al., 2013; Moore, Shartle, Faudskar, Matlin, & Brennan, 2013; 
Pollack et al., 2010).  MRCI scores in this study represented medication complexity. 
This research study used a standard protocol of evaluating patients medication 
regimens (see MTM services in Chapter 2); the results showed that there was no 
association between receiving MTM pharmacist telephonic support on reducing 
medication complexity (p= 0.84).  The patient’s medication regimens were not, however, 
simplified as a result of the MTM pharmacist consultation.  This finding is consistent 
with other studies (George et al., 2004; Libby et al., 2013; Mansur et al., 2012) that found 
that it is very difficult for the pharmacist to quantify regimen complexity without using a 
reliable tool such as the MRCI index.  When comparing two medication regimens with 
the same medication counts side by side, both regimens may look very similar, when in 
fact, they are not (Libby et al., 2013).  The common practice of using a simple medication 
count ignores medication regimen complexity.  This was evident in this study and its 
conclusion that complexity was not reduced as a result of the consultation by the 
pharmacist. 
Comorbidities and Complexity 
When controlling for covariates (age, gender, and comorbidities), age and gender 




medication complexity.  This finding is consistent with other studies (Corsonello et al., 
2009; Mansur, Weiss, & Beloosesky, 2012).  However, in the current study, results found 
that comorbidities were statistically correlated with medication complexity (r=0.10, 
p=0.01), although the strength of this correlation was weak.  This finding adds to the 
earlier findings by Libby et al. (2011) that disease states such as T2DM, Geriatric 
Depression, and HIV are more complex in treatment.  More than 45% of patients in the 
three cohort disease states in the present study were on more than 11 different 
medications, compared to 28% in the hypertension cohort.  This group’s mean MRCI 
scores ranged from 23–26, versus 18 in the hypertension cohort.  Medications that were 
prescribed outside of the cohort-defining disease medications also contributed the most to 
the MRCI patient scores.  The complexity of treating T2DM is that the treatment consists 
of the medications for the disease itself, plus treatment medications for the comorbidities 
that present due to the complications of the disease (ADA, 2012; Qaseem et al., 2012).  
These treatment regimens are often complex, intrusive, and inconvenient for the patient 
often-influencing medication adherence, as noted by Qaseem et al. (2012).  
Intensive diabetes control includes using medications to control the diabetes itself, 
but also preventative medications to prevent diabetes-related complications (ADA, 2013).  
Nonadherence affects not only a patient’s T2DM itself, but also  any diabetes-related 
complications such as hypertension, heart disease, and kidney disease that they may also 
have (ADA, 2013). Treatment of diabetes thus presents clinical challenges to MTM 




MTM Pharmacist Telephonic Support and Medication Adherence 
Research Question 2: Is there an association between receiving medication 
therapy management pharmacist telephonic support and medication adherence in 
Medicare Part D beneficiaries having T2DM as measured by a change in MPR 
percentages after controlling for MRCI scores? 
Medication adherence has been defined as the degree to which patients take their 
medications that have been prescribed to them by their health care providers (Osterberg 
& Blaschke, 2005).  Adherence can vary across the different chronic illnesses, from 
minimal to very significant (Ingersoll & Cohen, 2008).  Adherence was significant with 
less complex disease conditions such as hypertension or dyslipidemia as compared to 
more complex disease conditions such as T2DM, Geriatric depression or Asthma (Moore 
et al., 2013).  Consequences of nonadherence or limited adherence to T2DM medical 
regimens may result in lack of glycemic control, with downstream increases seen in 
increased associated medical costs (Moore et al., 2013; Pollack, Chastek, Williams, & 
Moran, 2010). 
There are two preferred methods used for measuring medications adherence, 
Medication Possession Ratio (MPR) and Proportion of Days Covered (PDC).  For this 
study, I focused on the MPR.  The MPR is a ratio that reflects the proportion of days 
during a defined period that a patient had possession of any of the drugs used to treat an 
illness (Choudhry et al., 2009; Karve et al., 2008; Karve et al., 2009; Nau, 2012).   
When using MPR, the ratios are always between 0 and 1 and may be represented 




standard acceptance for adherence (Osterberg & Blaschke, 2005).  The reported 
adherence rate reflects the percent of patients who achieved a high level of adherence to 
the target class of drugs.  Adherence to a complex disease such as T2DM is difficult for 
older adults as the medication regimen is complex.   
In my study, the base adherence (pre-treatment) mean ratios for the T2DM 
intervention group were 0.77 (77%), and T2DM control group were 0.74 (74%).  The 
post-treatment mean ratio of the T2DM intervention group was 0.78 (78%) and control 
was 0.73 (73%).  Results of my study showed that both the intervention and control 
group remained below the industry standard of acceptable adherence rate of 0.80 or 80% 
(Osterberg & Blaschke, 2005).  Medication Therapy Management pharmacists may have 
improved patient outcomes in other arenas in patient care (problem solving, medication 
costs, etc.).  However, patients remained vulnerable to possible adverse events of being 
non-adherent leading to increased risks for all cause hospitalization and mortality (Ho et 
al., 2006; Lau & Nau, 2004; Yang, 2009).  Insurers, self-insured employers, and 
government agencies primarily will shoulder the increased medical costs and medications 
(Shrank, Porter, Jain, & Choudhry, 2009).  The low adherence rates of the T2DM cohort 
in my study are consistent with existing literature representing complexity with this 
chronic disease (Choudhry et al., 2011; Corsonello et al., 2009; Pollack, Chastek, 
Williams, & Moran, 2010).  The under recognition of medication nonadherence in older 
adults with T2DM can have adverse consequences and it is important that MTM 




My study results found there was no significant difference between receiving 
MTM pharmacist counseling and medication adherence (p=0.36) even after controlling 
for medication complexity (p=0.07).  This finding correlates with other studies that have 
compared regimen complexity with medication adherence (Moore et al., 2013; Pollack, 
Chastek, Williams & Moran, 2010).  However, study results did identify a significant 
difference between medication adherence and medication complexity (p=0.034).  Results 
of this study showed that with older adults T2DM, complex medication regimens 
influenced medication adherence.  This result is important to PBM’s and MTM 
pharmacists, when evaluating medication regimens.  Complexity is an important factor to 
consider when trying to increase medication adherence.  Multiple day dosing, complex 
instructions and multiple trips to the pharmacy have been implicated for the failure of 
completion of first fill or refills of prescriptions (Choudhry et al., 2011; Karter, et al., 
2009; Ho et al., 2006).  This study results highlight an essential aspect of the therapeutic 
cascade that may be burdensome to the patient.  These results add to current literature in 
support of the importance of considering medication complexity on medication adherence 
especially in the T2DM population (Choudhry et al., 2011; Corsonello et al., 2009; 
Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky, 2012; Nam et al., 2011).   
Current literature supports patient factors such as depressed economic status, and 
cognitive/physical impairment, are difficult modifiable correlates of nonadherence 
(Corsonello et al., 2009; Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky, 2012; 
Nam et al., 2011).  However, polypharmacy, reducing adverse drug events and regimen 




2011; Corsonello et al., 2009; Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky, 
2012; Nam et al., 2011).  Despite the numerous studies that exist around medication 
nonadherence, some grey areas still exist in the understanding of all the factors involved 
in nonadherence in older adults.  Medication Therapy Management pharmacists have the 
opportunity to work collectively with the physician and patient to offer solutions that will 
help increase medication adherence in this complex patient population.   
Limitations of the Study 
There were several limitations to this study:  
• I used archival data from a previous study of health care in a large PBM.  
The selection, quality, included variables, and the method of data 
collection were not under my control and validation was not possible.    
• Since the MRCI index score was used retrospectively and not 
prospectively, the MTM pharmacists did not use this tool when evaluating 
patient profiles for medication complexity. This may have influenced 
outcomes regarding reducing medication complexity and increasing 
medication adherence. 
• Only records of oral maintenance medications pertinent to the disease 
itself, or to existing comorbidities, and preventive maintenance 
medications were considered for my study.  I did not consider the use of 
other medications such as anti anxiety, sleep aids, and or as needed pain 
medications. Libby et al. (2013) tracked all the over the counter 




OTCs, added another 12% to the total MRCI scores in the Diabetes 
Mellitus patient cohot. 
Recommendations 
This study represents a first step towards filling the information gap on research 
involving PBM MTM pharmacists in telephonic consulting roles on medication 
complexity and nonadherence.  Although no statistically significant results were 
identified between the independent variable MTM pharmacist counseling program and 
the dependant variables medication adherence (MPR) and medication complexity 
(MRCI),  a causational link between comorbidities and medication complexity could not 
be ruled out.   
The results from research questions 1 and 2 contribute to existing knowledge of 
comorbidities adding to disease state complexity, and medication complexity, and their 
effects on medication adherence.  Based on these results, it is important that PBM MTM 
pharmacists consider medication complexity and using a validated tool such as the MRCI 
index when evaluating complex medication regimens to increase medication adherence.  
Further studies are needed to evaluate the use of the MRCI index prospectively by PBM 
MTM pharmacists on medication adherence and medication complexity.  
Implications 
 Implications for Social Change 
The number of medications taken by older adult’s increases with age and disease-
related comorbidities carry a high risk of polypharmacy (Budnitz, Lovegrove, Shehab, & 




2012).  Polypharmacy among older adults with T2DM has been associated with poor 
adherence, increased risk of adverse events, leading to hospitalizations, emergency 
department visits, and all cause mortality (Chisholm-Burns et al., 2010; Congressional 
Budget, 2010; Doggrell, 2010; Moore et al., 2013; Roebuck et al., 2011; Yang et al., 
2009).  Medication complexity and nonadherence have negative effects on medication 
adherence and therepeutic outcomes which could undermine effective treatments in 
complex chronic diseases such as T2DM (Choudhry et al., 2011; Libby et al., 2013; 
Pollack, Chastek, Williams, & Moran, 2010).  
Pharmacy Benefit Management MTM telephonic programs provide a unique 
opportunity to promote health by assisting patients to receive the appropriate medication 
and to adhere to their medication regimens.  The MRCI index is a proven method of 
identifying medication complexity and would provide PBM MTM pharmacists a more 
efficient approach to identifying high-risk patients.  This would allow for targeted 
interventions to improve adherence and achieve optimum outcomes in diabetes 
management, potentially reducing morbidity and mortality.  Using medication 
complexity as an indicator to identify medication nonadherence may be a useful strategy 
for PBMs to reduce long-term costs and decrease downstream costs to insurance 
companies and patients (Congressional Budget, 2010; Lawrence et al., 2012; Shrank, 
Porter, Jain, & Choudhry, 2009). 
Implications for Stages of Theory Change 
This study strengthens the overall concept of the theory, as it relates to patient 




understood followed by different strategies by pharmacists in consulting patients on their 
medications.  As the individual builds self-efficacy, the individual's decisional balance 
has a positive shift forward propelling the individual to the next stage (Prochaska et al., 
2008).  Increasing self-efficacy is important to maintaining a new behavior, such as being 
medication adherent.  Pharmacists are instrumental in factors influencing adherence, 
including patient’s comprehension of medication regimen and its benefits, potential side 
effects, and costs (Moczygemba, Barner, Gabrillo, & Godley, 2008; Moore et al., 2013; 
Patwardhan, Duncan, Murphy, & Pegus, 2012; Rodriguez de Bittner & Zaghab, 2011; 
Schnipper et al., 2006 ). 
Recommendations for Practice 
The results of my study, while not confirming statistically significance, suggest 
that there may be some merit in pursuing the use of the MRCI index as a valid tool for 
evaluating medication complexity as a means to increase medication adherence.  The lack 
of statistical significance should not be interpreted to mean that MTM pharmacists were 
not effective in increasing medication adherence.  This study showed that it was not 
demonstrable in this study.  As was pointed out in Chapter 2, it is important to evaluate 
all the factors that influence medication nonadherence, including medication complexity 
(Ingersoll & Cohen, 2008; Libby et al., 2013; Mansur, Weiss, & Beloosesky, 2012; 
Pollack et al., 2010).  When evaluating medication complexity, it is important to use a 
validated tool such as the MRCI index rather that medication count (George et al., 2004).  




into using the MRCI index as a tool to assist MTM pharmacists when evaluating 
medication profiles for medication complexity. 
Conclusion 
For older adults, treatment of T2DM will require continuous medical care and 
patient self-management including using preventative strategies beyond glycemic control 
(ADA, 2013).  Preventive strategies include cardiovascular disease risk management. 
Type 2 Diabetes Mellitus has been shown to be major risk factor for cardiovascular 
disease, increasing the risk for morbidity and mortality for these individuals (ADA, 
2013).  Treatment strategies include high blood pressure management, dyslipidemia/ lipid 
management and coronary heart disease prevention (ADA, 2013).  The care of older 
adults with T2DM is complicated by their comorbidities and poly pharmacy. Pharmacists 
are integral in the ongoing patient self-management education.  Pharmacists’ support is 
critical to preventing acute and long-term complications. 
Baseline data from this study indicate that the T2DM cohort were not medication 
adherent and are vulnerable to possible long-term complications.  Pharmacy benefit 
managers and MTM pharmacists must consider not only the complications of the 
nonadherence to the individual but the increased downstream costs to the insurers, self-
insured employers, and government agencies.  There are many factors that influence 
medication nonadherence, medication complexity is a modifiable factor in medication 
nonadherence.   
Healthcare plans and providers continue looking into ways to measure quality 




incorporating measures of quality in an effort to evalute themselves, how employers 
choose plans and consumers decide who provides their care (Seabury, Lakdawalla, 
Dougherty, Sullivan & Goldman, 2015).  Medication adherence is an excellent entrant for 
quality measurement, for as medication adherence increases, regimen complexity and 
medical costs decrease, and clinical outcomes increase (Cutler & Everett, 2010; Seabury, 
Lakdawalla, Dougherty, Sullivan & Goldman, 2015; Viswanathan et al., 2012).  
Concerted efforts need to be made to increase awareness to PBM’s and MTM 
pharmacists involved with evaluating medication profiles the importance for evaluating  
medication complexity especially in complicated disease states such as T2DM.   More 
prospective studies are needed using the MRCI index as a means to evaluate regimen 
complexity.  Exploring this using a mixed study approach would be valuable for getting 
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Appendix A: Medication Regimen Complexity Index Section 
Dosage forms  (A) Weighting Dosing Frequency (B) Weighting 
    
Oral 
Capsules/Tablets 1 Once daily 1 
Gargles/Mouthwashes 2 Once daily as needed (prn) 0.5 
Gums/Lozenges 2 Twice daily  2 
Liquids 2 Twice daily prn 1 
Powders/ Granules 2 Three times daily 3 
Sublingual sprays/ tabs 2 Three times daily prn 1.5 
Topical 
Creams/ Gels/Ointments            2 Four times daily 4 
 
Dressings 3 Four times daily prn 2 
Patches 2 Every 12 hrs 2.5 
Sprays 
1 
Every 12 hrs prn 1.5 
 
Ear, Eye & Nose 
Ear drops/ creams/ 
ointments 
3 
Every 8 hrs  
3.5 
Eye drops/gels/ointments 3 Every 8 hrs prn 2 
Nasal drops/ cream/ointment 3 Every 6 hrs  4.5 
Nasal spray 
3 
Every 6 hrs prn 2.5 
 
Inhalation 
Accuhalers 3 Every 4 hrs 6.5 
Metered dose inhalers 4 Every 4 hrs prn 3.5 
Nebulizer 5 Every 2 hrs 12.5 
Dry powder inhaler 
3 






On alternate days or less 
frequently 
2 
Injections:    Prefilled 






   Additional Directions (C) Weighting 
   Break/ crush/ dissolve  1 
Multiple units at one time 
(e.g. 2 tablets, 2 
inhalations) 
1 
Variable dose (e.g. 1 to 2 
tablets, 2 or 3 inhalations 
1 
Take at specific time/s      
(e.g. at bedtime, at noon) 
1 
Relation to food (e.g. 
before or after meals, with 
a snack) 
1 
Take as directed 2 
Tapering/increasing dose 
or alternating dose (1 
tablet in the morning and 2 
tablets at bedtime) 
2 
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the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received 
this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If 
you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this 
communication and any attachments. 
From: Information.Governance@CVSCaremark.com 
[mailto:Information.Governance@CVSCaremark.com] 
Sent: Tuesday, November 04, 2014 3:33 PM 
To: Kemper, Dianne M. 
Subject: CIAR# 4149665 Status Update - Request Approved 
Information Governance and Privacy Operations 
CIAR Team 
A Confidential Information Access Request (CIAR) has been reviewed by the CIAR 
Team. 
CIAR Record: 4149665 
Project Name: Dissertation: Analysis of telephonic pharmacist counseling 
This CIAR is now APPROVED. 
Click on the hyperlink provided above to access the CIAR record. 
Please contact Information.Governance@CVSCaremark.com if you have any 
questions. 
This notification has been sent to: 
Submitter 
Requestor 
CC: Analytics Approver 
Information Asset Steward / Custodian 
You are receiving this email because of your assigned responsibility within the CIAR 
record. This is a system generated email. 
eGRCNOTCIAR10. 
